CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11465428,1146542812,12,F,,20221012,20150907,20221013,EXP,,CA-ROCHE-1630210,ROCHE,,54,YR,,M,Y,,,20221013,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use;Prescribed overdose,1146542812,DE,,,,,,,,,1146542812,1,Bipolar disorder
12161166,121611666,6,F,,20220929,20160308,20221101,EXP,,CA-ABBVIE-10P-163-0641882-00,ABBVIE,,52,YR,,M,Y,,,20221101,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,121611666,OT,,,121611666,1,,200802,2920,DAY,121611666,1,HIV infection
14246609,1424660919,19,F,,20221212,20171204,20221224,EXP,,GB-AUROBINDO-AUR-APL-2017-43959,AUROBINDO,,85,YR,,M,Y,,,20221224,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,1424660919,OT,,,1424660919,4,,,152,DAY,1424660919,1,Cardiovascular event prophylaxis
14277495,142774957,7,F,,20221006,20171212,20221013,EXP,,GB-SHIRE-GB201732945,TAKEDA,,85,YR,,M,Y,,,20221013,,CN,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142774957,OT,,,,,,,,,142774957,1,Inflammatory bowel disease
14652614,1465261410,10,F,,20220922,20180319,20221003,EXP,,CA-APOTEX-2018AP007741,APOTEX,,44,YR,,M,Y,,,20221003,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1465261410,OT,,,1465261410,16,,,355,DAY,1465261410,1,Psychotic disorder
15095440,1509544010,10,F,20100629,20221108,20180702,20221121,EXP,,GB-GILEAD-2018-0347475,GILEAD,,43,YR,A,F,Y,43,KG,20221121,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1509544010,OT,,,1509544010,2,20171006,20180205,4,MON,1509544010,1,HIV infection
15123625,1512362528,28,F,20180205,20220601,20180710,20221110,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,A,F,Y,,,20221110,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362528,OT,,,1512362528,1,20171006,20180205,123,DAY,1512362528,1,HIV infection
15180832,1518083223,23,F,20100629,20221215,20180723,20221228,EXP,,GB-AUROBINDO-AUR-APL-2018-036898,AUROBINDO,,3,MON,,M,Y,,,20221228,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,1518083223,CA,,,1518083223,1,20090101,20100610,526,DAY,1518083223,1,HIV infection
15317962,1531796224,24,F,20171006,20221223,20180824,20221226,EXP,,PHHY2018GB074559,NOVARTIS,,3,MON,,M,Y,,,20221226,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,1531796224,OT,,,1531796224,2,20090101,20100610,526,DAY,1531796224,1,Foetal exposure during pregnancy
15357443,1535744325,25,F,20100629,20221004,20180906,20221018,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-NOVOPROD-619477,NOVO NORDISK,,43,YR,,F,Y,43,KG,20221018,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1535744325,HO,,,1535744325,3,20180205,20180205,122,DAY,1535744325,1,Product used for unknown indication
15361880,1536188018,18,F,20171006,20221125,20180907,20221129,EXP,,PHHY2018GB085930,NOVARTIS,,3,MON,,M,Y,,,20221129,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,1536188018,CA,,,1536188018,1,20171006,20180205,4,MON,1536188018,1,Foetal exposure during pregnancy
15363025,1536302521,21,F,20171006,20220927,20180907,20221011,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-125137,GB-NOVOPROD-619421,NOVO NORDISK,,3,MON,,M,Y,,,20221011,,HP,GB,GB,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Off label use;Trisomy 18;Ultrasound antenatal screen,1536302521,CA,,,1536302521,1,20180205,20180205,122,DAY,1536302521,1,HIV infection
15573679,1557367910,10,F,,20221214,20181101,20221224,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,A,M,Y,,,20221223,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,1557367910,HO,,,,,,,,,1557367910,1,HIV infection
15626751,1562675139,39,F,,20221214,20181116,20221222,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20221222,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Paranoia;Prescribed overdose;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1562675139,DE,,,,,,,,,1562675139,1,Bipolar disorder
16346235,163462355,5,F,,20221129,20190523,20221214,EXP,,CA-AUROBINDO-AUR-APL-2019-027597,AUROBINDO,,54,YR,,M,Y,,,20221214,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration,163462355,OT,,,,,,,,,163462355,1,HIV infection
16741532,167415325,5,F,,20221011,20190826,20221014,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080379,BRISTOL MYERS SQUIBB,,52,YR,A,M,Y,,,20221014,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,167415325,CA,,,,,,,,,167415325,1,HIV infection
16854746,168547464,4,F,20110101,20221220,20190926,20221227,EXP,,US-GILEAD-2019-0429522,GILEAD,,51,YR,A,F,Y,69.841,KG,20221227,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Quality of life decreased;Renal failure,168547464,OT,,,168547464,1,201107,20130812,2190,DAY,168547464,1,HIV infection
17244379,172443794,4,F,20070101,20221209,20200107,20221214,EXP,,US-GILEAD-2020-0445051,GILEAD,,59,YR,A,M,Y,140.59,KG,20221214,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Depression;Economic problem;Emotional distress;Foot fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Tooth loss,172443794,OT,,,172443794,1,2004,2009,913,DAY,172443794,1,HIV infection
17868459,1786845915,15,F,20100629,20221005,20200606,20221018,EXP,,GB-MACLEODS PHARMACEUTICALS US LTD-MAC2020026669,MACLEODS,,,,,,Y,,,20221017,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,1786845915,HO,,,1786845915,1,20171006,20180205,122,DAY,1786845915,1,HIV infection
17924500,179245003,3,F,,20221115,20200622,20221121,EXP,,CA-ROCHE-2621283,ROCHE,,52,YR,,M,Y,,,20221121,,HP,CA,,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,179245003,OT,,,,,,,,,179245003,1,HIV infection
17949727,1794972717,17,F,,20221101,20200626,20221114,EXP,CA-MHPD-E2B_02966351,CA-Accord-186554,ACCORD,,54,YR,A,M,Y,,,20221114,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,1794972717,DE,,,,,,,,,1794972717,1,Bipolar disorder
18045190,180451903,3,F,20110101,20221214,20200720,20221219,EXP,,US-GILEAD-2020-0480222,GILEAD,,42,YR,A,M,Y,83.914,KG,20221219,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Bone loss;Brain neoplasm;Depression;Femur fracture;Hip fracture;Osteonecrosis;Osteoporosis;Pain;Pain in extremity;Renal injury;Rib fracture;Upper limb fracture,180451903,OT,,,180451903,1,2004,2012,,,180451903,1,HIV infection
18078179,180781792,2,F,,20221006,20200728,20221018,EXP,,UG-CIPLA LTD.-2020UG04969,CIPLA,"Nyende L, Kalyesubula R, Sekasanvu E, Byakika-Kibwika P. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study. BMC Nephrology. 2020;21 (232):1 to 6",,,A,M,Y,,,20221018,,HP,UG,UG,EFAVIRENZ,Hyperkalaemia;Hypophosphataemia,180781792,OT,,,180781792,1,,,24,MON,180781792,1,HIV infection WHO clinical stage I
18119698,181196984,4,F,20170101,20220929,20200806,20221003,EXP,,US-GILEAD-2020-0487217,GILEAD,,56,YR,A,M,Y,180,KG,20221003,,LW,US,US,SUSTIVA,Anxiety;Asthenia;Bone density decreased;Bone loss;Chronic kidney disease;Creatinine urine increased;Emotional distress;Fatigue;Osteonecrosis;Osteopenia;Pain;Renal failure;Tooth disorder;Tooth loss,181196984,OT,,,181196984,1,20050107,201512,,,181196984,1,HIV infection
18187253,181872536,6,F,,20221104,20200824,20221117,EXP,CA-MHPD-E2B_03070843,CA-Accord-196145,ACCORD,,,,,M,Y,,,20221117,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,181872536,DE,,,,,,,,,181872536,1,Product used for unknown indication
18225618,182256183,3,F,,20221107,20200903,20221115,EXP,,CA-AstraZeneca-2020SF09863,ASTRAZENECA,,54,YR,,M,Y,,,20221115,,MD,CA,,SUSTIVA,Depression;Drug interaction,182256183,OT,,,,,,,,,182256183,1,Product used for unknown indication
18486497,184864972,2,F,,20220926,20201110,20221004,EXP,,CA-AstraZeneca-2020SF45143,ASTRAZENECA,,44,YR,,M,Y,,,20221004,,MD,CA,,SUSTIVA,Depression;Drug interaction;Psychiatric decompensation,184864972,HO,,,,,,,,,184864972,1,Bipolar disorder
18531452,185314522,2,F,,20221107,20201122,20221115,EXP,,CA-JNJFOC-20201124162,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20221115,,HP,CA,CA,SUSTIVA,Abdominal pain;Anxiety;Constipation;Gastric infection;Muscle rigidity;Off label use;Pain;Product use in unapproved indication;Rebound effect;Retching;Salivary hypersecretion;Sedation,185314522,HO,,,185314522,12,,,161,DAY,185314522,1,Major depression
18544053,185440534,4,F,,20221012,20201124,20221018,EXP,,CA-JNJFOC-20201125727,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20221018,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,185440534,HO,,,,,,,,,185440534,1,Depression
18910584,189105844,4,F,,20221004,20210218,20221013,EXP,,CA-ROCHE-2772723,ROCHE,,54,YR,,M,Y,,,20221011,,HP,CA,,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189105844,DE,,,,,,,,,189105844,1,Bipolar disorder
18947860,189478604,4,F,,20221213,20210226,20221220,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053471,GLAXOSMITHKLINE,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1891",,,,,Y,,,20221220,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,189478604,HO,,,,,,,,,189478604,1,Depression
19081584,190815848,8,F,20060602,20221129,20210331,20221207,EXP,,CA-AstraZeneca-2020SF04539,ASTRAZENECA,,44,YR,,M,Y,,,20221207,,MD,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,190815848,OT,,,190815848,1,20070729,20070730,2,DAY,190815848,1,Depression
19215171,192151713,3,F,20190614,20221014,20210504,20221027,EXP,,US-GILEAD-2021-0527872,GILEAD,,63,YR,A,M,Y,113.38,KG,20221027,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dyspareunia;Emotional distress;Gait disturbance;Insomnia;Multiple fractures;Osteoporosis;Pain;Physical disability;Renal failure;Spinal fracture,192151713,OT,,,192151713,1,2004,202009,4602,DAY,192151713,1,HIV infection
19901857,199018572,2,F,,20221104,20210930,20221115,EXP,,IN-CIPLA LTD.-2021IN06388,CIPLA,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. Indian Journal of Sexually Transmitted Diseases and AIDS. 2020;41 (1):113 to 115",23,YR,,M,Y,,,20221115,,HP,IN,IN,EFAVIRENZ,Depression;Drug interaction;Euphoric mood;Insomnia;Irritability;Logorrhoea;Therapy non-responder,199018572,OT,,,,,,,,,199018572,1,HIV infection
19939207,199392073,3,F,,20221125,20211011,20221205,EXP,,CA-MYLANLABS-2021M1071036,MYLAN,,54,YR,,M,Y,,,20221205,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,199392073,DS,,,,,,,,,199392073,1,Bipolar disorder
20214238,202142384,4,F,,20221207,20211221,20221213,EXP,,US-GILEAD-2021-0560646,GILEAD,,,,A,M,Y,,,20221213,,LW,US,US,SUSTIVA,Chronic kidney disease;Renal failure,202142384,OT,,,202142384,1,2014,2018,,,202142384,1,HIV infection
20217592,202175929,9,F,20211120,20221010,20211222,20221013,EXP,,DE-TAKEDA-2021TUS079245,TAKEDA,,,,E,M,Y,,,20221013,,HP,DE,DE,EFAVIRENZ,C-reactive protein increased;Femur fracture,202175929,DS,,,202175929,1,20190107,20211227,38,DAY,202175929,1,Factor VIII deficiency
20222028,202220282,2,F,,20221027,20211223,20221103,EXP,,US-GILEAD-2021-0561992,GILEAD,,,,A,M,Y,57.143,KG,20221103,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Depression;Dysstasia;Emotional distress;Osteoporosis;Pain;Pain in extremity,202220282,OT,,,202220282,1,2014,,,,202220282,1,HIV infection
20230640,202306402,2,F,20100901,20221121,20211227,20221129,EXP,,US-GILEAD-2021-0562277,GILEAD,,53,YR,A,M,Y,63.492,KG,20221129,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fatigue;Gait disturbance;Glomerular filtration rate decreased;Hyperparathyroidism;Osteopenia;Osteoporosis;Pain;Rib fracture,202306402,OT,,,202306402,1,200510,201611,,,202306402,1,HIV infection
20301721,203017212,2,F,20160101,20221019,20220105,20221026,EXP,,US-GILEAD-2022-0563749,GILEAD,,,,A,M,Y,117.01,KG,20221026,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Depression;Emotional distress;Gait disturbance;General physical health deterioration;Pain;Thrombosis,203017212,OT,,,203017212,1,2014,201612,,,203017212,1,HIV infection
20303092,203030922,2,F,20080101,20221126,20220106,20221129,EXP,,US-GILEAD-2022-0563736,GILEAD,,53,YR,A,F,Y,81.646,KG,20221128,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Depression;Eating disorder;Emotional distress;Foot fracture;Gait disturbance;General physical health deterioration;Lower limb fracture;Osteopenia;Osteoporosis;Pain;Renal impairment;Wrist fracture,203030922,OT,,,203030922,1,2008,201505,,,203030922,1,HIV infection
20303409,203034092,2,F,20140101,20221118,20220106,20221123,EXP,,US-GILEAD-2022-0563851,GILEAD,,,,A,F,Y,81.633,KG,20221123,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Osteopenia;Osteoporosis;Pain,203034092,OT,,,203034092,1,2004,2016,,,203034092,1,HIV infection
20310617,203106173,3,F,,20221125,20220107,20221129,EXP,,CA-ABBVIE-22K-028-4223963-00,ABBVIE,,,,A,M,Y,,,20221129,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,203106173,DE,,,,,,,,,203106173,1,Bipolar disorder
20353240,203532402,2,F,20120101,20221002,20220119,20221007,EXP,,US-GILEAD-2022-0565864,GILEAD,,,,A,M,Y,48.98,KG,20221007,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood creatinine increased;Chronic kidney disease;Dysstasia;Emotional distress;Gait disturbance;Insomnia;Pain;Pollakiuria;Protein total increased;Renal impairment;Renal injury,203532402,HO,,,203532402,1,2010,2010,,,203532402,1,HIV infection
20359439,203594392,2,F,20070801,20221115,20220121,20221118,EXP,,US-GILEAD-2022-0565923,GILEAD,,37,YR,A,F,Y,85.714,KG,20221118,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Arthralgia;Bone demineralisation;Bone disorder;Depression;Emotional distress;Foot fracture;Gait disturbance;Hand fracture;Osteoarthritis;Osteoporosis;Pain,203594392,OT,,,203594392,1,2005,201806,,,203594392,1,HIV infection
20359598,203595982,2,F,20070101,20221121,20220121,20221128,EXP,,US-GILEAD-2022-0565669,GILEAD,,,,A,M,Y,127.91,KG,20221128,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Bone demineralisation;Discomfort;Emotional distress;Fatigue;Intervertebral disc protrusion;Lumbar spinal stenosis;Osteoporosis;Pain;Renal impairment;Vitamin D deficiency,203595982,OT,,,203595982,1,2002,2007,,,203595982,1,HIV infection
20361137,203611373,3,F,20120101,20221201,20220121,20221207,PER,,US-GILEAD-2022-0565857,GILEAD,,,,A,M,Y,79.365,KG,20221207,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;End stage renal disease;Loss of personal independence in daily activities;Pain;Pneumonia;Renal failure,203611373,HO,,,203611373,1,2004,2012,,,203611373,1,HIV infection
20361222,203612222,2,F,,20221104,20220121,20221109,EXP,,US-GILEAD-2022-0565664,GILEAD,,,,A,F,Y,87.543,KG,20221109,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Emotional distress;Gait disturbance;General physical health deterioration;Osteopenia;Osteoporosis;Pain,203612222,OT,,,203612222,1,2016,201903,,,203612222,1,HIV infection
20363820,203638202,2,F,20100101,20221013,20220121,20221018,EXP,,US-GILEAD-2022-0566013,GILEAD,,,,A,F,Y,85.714,KG,20221018,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Emotional distress;Hip arthroplasty;Osteoporosis;Pain,203638202,OT,,,203638202,1,2004,2011,,,203638202,1,HIV infection
20364374,203643742,2,F,20181101,20221012,20220121,20221017,PER,,US-GILEAD-2022-0565684,GILEAD,,66,YR,E,M,Y,61.224,KG,20221017,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone disorder;Emotional distress;Gait disturbance;Osteopenia;Pain,,,,,203643742,1,2010,201804,,,203643742,1,HIV infection
20365706,203657062,2,F,20180911,20221020,20220123,20221023,PER,,US-GILEAD-2022-0565899,GILEAD,,60,YR,A,F,Y,65.76,KG,20221023,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Arthropathy;Bone density decreased;Emotional distress;Gait disturbance;Musculoskeletal stiffness;Osteopenia;Pain,,,,,203657062,1,2007,201811,,,203657062,1,HIV infection
20367048,203670482,2,F,20160101,20221028,20220123,20221103,PER,,US-GILEAD-2022-0566484,GILEAD,,,,A,M,Y,71.202,KG,20221103,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;General physical health deterioration;Pain,,,,,203670482,1,2010,201605,,,203670482,1,HIV infection
20367218,203672182,2,F,20120101,20221122,20220123,20221124,EXP,,US-GILEAD-2022-0566537,GILEAD,,,,A,M,Y,70.295,KG,20221124,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone loss;Bone pain;Emotional distress;Gait disturbance;Pain;Pain in extremity;Renal disorder;Renal impairment;Renal injury,203672182,OT,,,203672182,2,2009,,,,203672182,1,HIV infection
20367543,203675432,2,F,20130101,20221011,20220124,20221018,EXP,,US-GILEAD-2022-0565789,GILEAD,,,,A,F,Y,93.424,KG,20221017,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Pain;Renal disorder,203675432,OT,,,203675432,1,2005,2017,,,203675432,1,HIV infection
20368213,203682132,2,F,20110101,20221205,20220124,20221213,EXP,,US-GILEAD-2022-0566426,GILEAD,,,,A,M,Y,61.23,KG,20221213,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Bone loss;Emotional distress;Multiple fractures;Osteoporosis;Pain;Renal injury,203682132,OT,,,203682132,1,2009,,,,203682132,1,HIV infection
20381594,203815942,2,F,20140801,20221102,20220127,20221108,EXP,,US-GILEAD-2022-0566436,GILEAD,,59,YR,A,M,Y,96.599,KG,20221108,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Emotional distress;Osteoporosis;Pain,203815942,OT,,,203815942,1,2006,201701,,,203815942,1,HIV infection
20386757,203867572,2,F,20070101,20221129,20220127,20221202,EXP,,US-GILEAD-2022-0566508,GILEAD,,,,A,M,Y,51.256,KG,20221202,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Nocturia;Pain;Pollakiuria;Renal failure;Renal injury,203867572,OT,,,203867572,1,2004,2007,,,203867572,1,HIV infection
20431576,204315763,3,F,,20221025,20220204,20221026,EXP,,IN-TAKEDA-2022TUS007346,TAKEDA,"Kachhwaha A, Rohila AK, Tripathi S, Meena DS, Khichar S, Kumar D. Acute myocardial infarction in hemophilia a with HIV and hyperhomocysteinemia-a rare case report. CARDIOVASCULAR AND HEMATOLOGICAL DISORDERS-DRUG TARGETS. 2021;xx:1-3",42,YR,,M,Y,,,20221026,,HP,IN,IN,EFAVIRENZ,Acute myocardial infarction,204315763,OT,,,,,,,,,204315763,1,Factor VIII deficiency
20452091,204520912,2,F,20120701,20221104,20220209,20221109,PER,,US-GILEAD-2022-0569147,GILEAD,,,,,M,Y,81.633,KG,20221109,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Body height decreased;Bone demineralisation;Bone pain;Emotional distress;Fatigue;Gait disturbance;Osteopenia;Pain;Proteinuria;Renal impairment,204520912,OT,,,204520912,1,2007,201903,,,204520912,1,HIV infection
20456744,204567442,2,F,20091001,20221205,20220210,20221208,EXP,,US-GILEAD-2022-0569165,GILEAD,,38,YR,A,M,Y,126.98,KG,20221208,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Bone demineralisation;Bone pain;Chronic kidney disease;Depressed mood;Depression;Emotional distress;Fatigue;Fracture pain;Osteopenia;Osteoporosis;Pain;Tibia fracture,204567442,HO,,,204567442,1,2006,2014,,,204567442,1,HIV infection
20457529,204575292,2,F,20080101,20221026,20220210,20221103,EXP,,US-GILEAD-2022-0569525,GILEAD,,,,A,M,Y,79.365,KG,20221103,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;Gait disturbance;Hip fracture;Hyperparathyroidism;Hypertension;Metabolic acidosis;Osteoporosis;Pain;Renal injury;Spinal fracture,204575292,OT,,,204575292,1,2004,201107,,,204575292,1,HIV infection
20472901,204729012,2,F,20160101,20221028,20220215,20221103,PER,,US-GILEAD-2022-0569023,GILEAD,,53,YR,A,M,Y,95.254,KG,20221103,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Emotional distress;Fatigue;Pain;Renal impairment,204729012,OT,,,204729012,1,2009,200411,,,204729012,1,HIV infection
20476272,204762722,2,F,20180401,20221209,20220215,20221215,EXP,,US-GILEAD-2022-0569123,GILEAD,,53,YR,A,M,Y,70.307,KG,20221215,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Emotional distress;Osteopenia;Osteoporosis;Pain,204762722,OT,,,204762722,1,2016,201611,,,204762722,1,HIV infection
20516396,2051639619,19,F,,20221216,20220225,20221226,EXP,,GB-ORGANON-1711GBR010764,ORGANON,,85,YR,,M,Y,,,20221226,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,2051639619,OT,,,2051639619,8,,,152,DAY,2051639619,1,Cardiovascular event prophylaxis
20579632,205796323,3,F,20120101,20221026,20220310,20221103,EXP,,US-GILEAD-2022-0572733,GILEAD,,,,A,M,Y,132.88,KG,20221103,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Hypertension;Insomnia;Nausea;Nocturia;Pain;Renal impairment,205796323,HO,,,205796323,1,2001,2002,,,205796323,1,HIV infection
20586748,205867482,2,F,20160101,20221221,20220313,20221227,EXP,,US-GILEAD-2022-0572850,GILEAD,,,,A,F,Y,,,20221227,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain,205867482,OT,,,205867482,1,2004,2018,,,205867482,1,Product used for unknown indication
20612453,206124533,3,F,,20221202,20220318,20221209,EXP,,CA-MYLANLABS-2022M1020580,MYLAN,,54,YR,,M,Y,,,20221209,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,206124533,DE,,,,,,,,,206124533,1,Bipolar disorder
20661387,206613872,2,F,20140901,20221116,20220401,20221121,EXP,,US-GILEAD-2022-0575284,GILEAD,,54,YR,A,M,Y,80.726,KG,20221120,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Dysstasia;Emotional distress;Pain,206613872,OT,,,206613872,1,2006,200901,,,206613872,1,HIV infection
20662386,206623863,3,F,20220121,20221107,20220401,20221116,EXP,,FR-AUROBINDO-AUR-APL-2022-007807,AUROBINDO,,,,A,M,Y,92,KG,20221117,,HP,FR,FR,EFAVIRENZ,Disease recurrence;Drug interaction;Hepatitis C,206623863,OT,,,206623863,2,20210528,20210820,84,DAY,206623863,1,HIV infection
20664467,206644672,2,F,20031101,20221116,20220401,20221121,EXP,,US-GILEAD-2022-0575243,GILEAD,,39,YR,A,M,Y,95.238,KG,20221121,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Blood creatinine increased;Chronic kidney disease;Dysstasia;Emotional distress;Hypertension;Pain,206644672,OT,,,206644672,1,200310,200610,,,206644672,1,HIV infection
20665752,206657522,2,F,20210528,20221108,20220402,20221117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-034348,BRISTOL MYERS SQUIBB,,,,A,M,Y,92,KG,20221117,,HP,FR,FR,EFAVIRENZ,Drug interaction;Hepatitis C,206657522,OT,,,206657522,2,20210528,20210820,12,WK,206657522,1,HIV infection
20802683,2080268332,32,F,20120521,20221110,20220509,20221122,EXP,,GB-HORMOSAN PHARMA GMBH-2019-03347,LUPIN,,43,YR,,F,Y,43,KG,20221122,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Off label use,2080268332,HO,,,2080268332,2,20171006,20180205,4,MON,2080268332,1,HIV infection
20816893,2081689314,14,F,20171006,20221011,20220512,20221020,EXP,,GB-MACLEODS PHARMA UK LTD-MAC2022035517,MACLEODS,,,,,,Y,,,20221020,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,2081689314,CA,,,2081689314,1,20171006,20180205,122,DAY,2081689314,1,Product used for unknown indication
20858432,208584323,3,F,,20221019,20220521,20221026,EXP,,CA-009507513-2205CAN005476,MERCK,,54,YR,,M,Y,,,20221026,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208584323,OT,,,,,,,,,208584323,1,HIV infection
20862425,208624253,3,F,,20221130,20220523,20221202,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039291,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20221202,,CN,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Hospitalisation;Intentional product use issue;Loss of personal independence in daily activities,208624253,OT,,,,,,,,,208624253,1,HIV infection
20864521,208645213,3,F,20190101,20220928,20220524,20221003,EXP,,US-GILEAD-2022-0582426,GILEAD,,,,A,M,Y,109.75,KG,20221003,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Bone density decreased;Carotid artery disease;Chronic kidney disease;Constipation;Dysstasia;Emotional distress;Erectile dysfunction;Gait disturbance;Impaired work ability;Loss of personal independence in daily activities;Pain,208645213,OT,,,208645213,1,2014,201908,,,208645213,1,HIV infection
20871993,208719933,3,F,,20220715,20220525,20221028,EXP,,SE-VIIV HEALTHCARE LIMITED-SE2021267531,VIIV,,,,,,Y,,,20221028,,HP,SE,SE,EFAVIRENZ,Drug resistance,208719933,OT,,,,,,,,,208719933,1,HIV infection
20871996,208719963,3,F,,20220715,20220525,20221028,EXP,,SE-GLAXOSMITHKLINE-SE2021267531,GLAXOSMITHKLINE,,,,,,Y,,,20221028,,HP,SE,SE,EFAVIRENZ,Drug resistance,208719963,OT,,,,,,,,,208719963,1,HIV infection
20876174,208761742,2,F,20100101,20221010,20220526,20221012,PER,,US-GILEAD-2022-0582507,GILEAD,,51,YR,A,F,Y,65.76,KG,20221012,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Depression;Emotional distress;Foot fracture;Gait disturbance;Loss of personal independence in daily activities;Musculoskeletal disorder;Osteopenia;Pain;Pain in extremity;Patella fracture;Renal disorder,,,,,208761742,1,2002,2006,,,208761742,1,HIV infection
20877650,208776503,3,F,,20221014,20220526,20221021,EXP,,CA-APOTEX-2022AP008239,APOTEX,,54,YR,,M,Y,,,20221021,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208776503,OT,,,,,,,,,208776503,1,HIV infection
20883079,208830793,3,F,,20221019,20220527,20221024,EXP,,CA-BAUSCH-BL-2022-012991,BAUSCH AND LOMB,,54,YR,,M,Y,,,20221024,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208830793,HO,,,,,,,,,208830793,1,Depression
20884066,208840663,3,F,,20221130,20220527,20221202,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084848,VIIV,,,,,,Y,,,20221202,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840663,DE,,,,,,,,,208840663,1,HIV infection
20884074,208840743,3,F,,20221130,20220527,20221202,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084848,GLAXOSMITHKLINE,,,,,,Y,,,20221202,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,208840743,DE,,,,,,,,,208840743,1,HIV infection
20892665,208926653,3,F,,20221021,20220531,20221103,EXP,,CA-ABBVIE-22K-028-4414704-00,ABBVIE,,54,YR,,M,Y,,,20221103,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208926653,HO,,,,,,,,,208926653,1,HIV infection
20898441,208984413,3,F,,20221128,20220601,20221212,EXP,,CA-AUROBINDO-AUR-APL-2022-018761,AUROBINDO,,54,YR,,M,Y,,,20221212,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208984413,OT,,,,,,,,,208984413,1,Psychotic disorder
20902432,209024322,2,F,,20221208,20220601,20221214,EXP,,UG-MYLANLABS-2022M1041517,MYLAN,,37,YR,,F,Y,,,20221214,,HP,UG,UG,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209024322,OT,,,209024322,1,20210106,20210105,958,DAY,209024322,1,HIV infection
20907220,209072203,3,F,,20221115,20220602,20221118,EXP,,CA-ALLERGAN-2217864US,ALLERGAN,,,,,M,Y,,,20221118,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209072203,OT,,,,,,,,,209072203,1,Psychotic disorder
20923847,209238474,4,F,,20221115,20220607,20221116,EXP,,CA-ROCHE-3109019,ROCHE,,54,YR,,M,Y,,,20221116,,HP,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209238474,HO,,,,,,,,,209238474,1,Depression
20942966,209429662,2,F,,20221018,20220610,20221028,EXP,,CA-TEVA-2022-CA-2043060,TEVA,,52,YR,A,M,Y,,,20221028,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,209429662,OT,,,,,,,,,209429662,1,HIV infection
20951752,209517522,2,F,,20221012,20220613,20221014,EXP,,CA-ROCHE-3111593,ROCHE,,52,YR,,M,Y,,,20221014,,HP,CA,,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,209517522,OT,,,,,,,,,209517522,1,HIV infection
20969211,2096921144,44,F,,20221205,20220616,20221211,EXP,,GB-ABBVIE-22K-167-4434184-00,ABBVIE,,,,,M,Y,,,20221211,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,2096921144,OT,,,2096921144,2,20100610,20180205,123,DAY,2096921144,1,Maternal exposure timing unspecified
20993425,209934252,2,F,,20221107,20220622,20221115,EXP,,CA-JNJFOC-20220629261,JOHNSON AND JOHNSON,,54,YR,A,M,Y,,,20221115,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209934252,HO,,,,,,,,,209934252,1,Depression
21009047,210090473,3,F,,20221019,20220627,20221024,EXP,,CA-BAUSCH-BL-2022-015915,BAUSCH AND LOMB,,54,YR,,M,Y,,,20221024,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210090473,DE,,,,,,,,,210090473,1,Bipolar disorder
21017702,210177022,2,F,,20221019,20220628,20221026,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK098175,VIIV,,,,,,Y,,,20221026,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210177022,OT,,,,,,,,,210177022,1,Bipolar disorder
21017703,210177032,2,F,,20221019,20220628,20221026,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK098175,GLAXOSMITHKLINE,,,,,,Y,,,20221026,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210177032,OT,,,,,,,,,210177032,1,Bipolar disorder
21022167,210221675,5,F,,20221215,20220629,20221219,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2022098218,VIIV,,,,,,Y,,,20221219,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Trisomy 18;Ultrasound antenatal screen,210221675,DE,,,210221675,1,20090101,20100610,526,DAY,210221675,1,Product used for unknown indication
21022189,210221895,5,F,,20221215,20220629,20221219,EXP,,GB-GLAXOSMITHKLINE-GB2022098218,GLAXOSMITHKLINE,,,,,,Y,,,20221219,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Trisomy 18;Ultrasound antenatal screen,210221895,CA,,,210221895,1,20090101,20100610,526,DAY,210221895,1,Product used for unknown indication
21039057,210390579,9,F,20100629,20221214,20220704,20221219,EXP,,GB-CIPLA LTD.-2022GB04083,CIPLA,,43,YR,,F,Y,,,20221219,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Drug abuse;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Off label use,210390579,CA,,,210390579,2,20100610,20180205,122,DAY,210390579,1,HIV infection
21124310,2112431016,16,F,20171006,20221221,20220725,20221227,EXP,,GB-CIPLA LTD.-2022GB04466,CIPLA,,16,WK,,M,Y,,,20221227,,MD,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,2112431016,HO,,,,,,,,,,,
21148760,211487602,2,F,,20221107,20220729,20221110,EXP,,CA-AstraZeneca-2022A267587,ASTRAZENECA,,54,YR,,M,Y,,,20221110,,MD,CA,,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,211487602,OT,,,,,,,,,211487602,1,Bipolar disorder
21163555,211635552,2,F,,20221031,20220802,20221108,EXP,,CA-AstraZeneca-2022A269156,ASTRAZENECA,,,,,M,Y,,,20221108,,MD,CA,,SUSTIVA,Depression;Drug interaction,211635552,HO,,,,,,,,,211635552,1,Product used for unknown indication
21164775,211647755,5,F,20120521,20221102,20220803,20221107,EXP,,PHHY2018GB081566,NOVARTIS,,43,YR,,F,Y,,,20221107,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy;Off label use,211647755,CA,,,211647755,5,20090101,20100610,526,DAY,211647755,1,Product used for unknown indication
21172774,211727742,2,F,,20221107,20220804,20221115,EXP,,CA-AstraZeneca-2022A267471,ASTRAZENECA,,54,YR,,M,Y,,,20221115,,MD,CA,,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,211727742,OT,,,,,,,,,211727742,1,Bipolar disorder
21217161,212171612,2,F,20050101,20221108,20220816,20221116,EXP,,US-GILEAD-2022-0593520,GILEAD,,,,A,M,Y,154,KG,20221116,,CN,US,US,SUSTIVA,Anxiety;Arm amputation;Bone deformity;Bone disorder;Dental caries;Depression;Dysgraphia;Emotional distress;Feelings of worthlessness;Gait disturbance;Immobile;Impaired work ability;Kyphosis;Monoparesis;Multiple fractures;Osteogenesis imperfecta;Osteomyelitis;Pain;Paralysis;Scoliosis;Spinal cord infection;Spinal osteoarthritis;Tooth loss;Wheelchair user,212171612,OT,,,212171612,1,2004,20140407,,,212171612,1,HIV infection
21220297,212202978,8,F,20100629,20221125,20220817,20221210,EXP,,GB-AUROBINDO-AUR-APL-2018-044992,AUROBINDO,,43,YR,,F,Y,,,20221210,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Cleft lip and palate;Exposure during pregnancy;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy;Off label use;Trisomy 18;Ultrasound antenatal screen,212202978,OT,,,212202978,1,20171006,20180205,4,MON,212202978,1,HIV infection
21220860,212208603,3,F,20200801,20221014,20220817,20221025,EXP,,DK-AUROBINDO-AUR-APL-2022-032254,AUROBINDO,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports.. 2022;14(4):501-504.",50,YR,,M,Y,,,20221025,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,212208603,OT,,,,,,,,,212208603,1,HIV infection
21285914,212859142,2,F,20220628,20221205,20220902,20221219,30DAY,,US-VIIV HEALTHCARE LIMITED-US2022AMR124211,VIIV,,50,YR,,M,Y,87.528,KG,20221214,,HP,US,US,SUSTIVA,Product use in unapproved therapeutic environment;Treatment failure;Viral load increased,,,,,212859142,1,20220421,20220819,1,MON,212859142,1,HIV infection CDC category B
21291596,212915962,2,F,20220628,20221205,20220903,20221215,PER,,US-JNJFOC-20220904524,JOHNSON AND JOHNSON,,46,YR,A,M,Y,,,20221215,,HP,US,US,SUSTIVA,Product use in unapproved therapeutic environment;Treatment failure;Viral load increased,,,,,212915962,1,20220421,20220819,31,DAY,212915962,1,HIV infection CDC category B
21300996,213009965,5,F,20171006,20221010,20220907,20221012,EXP,,NVSC2018GB021870,NOVARTIS,,3,MON,,M,Y,,,20221012,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,213009965,CA,,,213009965,6,20171006,20100610,526,DAY,213009965,1,Foetal exposure during pregnancy
21335646,213356462,2,F,,20221012,20220915,20221019,EXP,,CA-ROCHE-3179140,ROCHE,,54,YR,,M,Y,,,20221019,,HP,CA,,EFAVIRENZ,Drug interaction;Psychiatric decompensation,213356462,OT,,,213356462,9,,,2,DAY,213356462,1,Psychotic disorder
21369015,213690152,2,F,,20221006,20220923,20221013,EXP,,US-CIPLA LTD.-2019US02860,CIPLA,"Ali MS, Kooragayalu S, Mba BI, Olsen FC.. Isolated myopathy: An unusual manifestation of inhaled Fluticasone Propionate and Ritonavir interaction. Archivos de Bronconeumologia. 2017;55 (4):223 to 225",58,YR,,M,Y,,,20221013,,MD,US,US,EFAVIRENZ,Drug interaction;Fall;Myopathy,213690152,HO,,,213690152,2,,,5,MON,213690152,1,HIV infection
21378969,213789693,3,F,,20221011,20220927,20221017,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2022-111960,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20221017,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213789693,OT,,,,,,,,,213789693,1,Product used for unknown indication
21379974,213799742,2,F,,20221011,20220927,20221014,EXP,,IN-GILEAD-2022-0598900,GILEAD,,,,N,,Y,,,20221014,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213799742,CA,,,,,,,,,213799742,1,HIV infection
21383725,213837252,2,F,,20221011,20220928,20221016,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP012269,STRIDES,,,,,,Y,,,20221016,,HP,IN,IN,EFAVIRENZ,Anencephaly;Foetal exposure during pregnancy;Neural tube defect;Spina bifida,213837252,OT,,,,,,,,,213837252,1,Product used for unknown indication
21385809,213858092,2,F,,20221010,20220928,20221017,EXP,,IN-MYLANLABS-2022M1096459,MYLAN,,,,,,Y,,,20221017,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,213858092,CA,,,,,,,,,213858092,1,HIV infection
21400770,214007701,1,I,,20220923,20221003,20221003,EXP,,IN-HETERO-HET2022IN02383,HETERO,,,,,,Y,,,20221003,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,214007701,OT,,,,,,,,,214007701,1,HIV infection
21400996,214009961,1,I,,20220923,20221003,20221003,EXP,,US-VIIV HEALTHCARE LIMITED-US2022AMR137748,VIIV,,,,,M,Y,,,20221003,,CN,US,US,EFAVIRENZ,Rash,,,,,,,,,,,214009961,1,Product used for unknown indication
21406618,214066181,1,I,,20220926,20221004,20221004,EXP,,IN-Vista Pharmaceuticals Inc.-2133442,VISTAPHARM,"Sarkar A. Concurrence of glucose-6-phosphate dehydrogenase deficiency in pregnancy. Journal of Obstetrics and Gynaecology (England) 42: 747-750, No. 5, Jul 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35068323/",27,YR,,F,Y,,,20221004,,HP,IN,IN,EFAVIRENZ,Anaemia;Exposure during pregnancy,214066181,HO,,,,,,,,,214066181,1,Pneumocystis jirovecii pneumonia
21408132,214081321,1,I,,20220926,20221004,20221004,EXP,,CA-AstraZeneca-2022A331479,ASTRAZENECA,,54,YR,,M,Y,,,20221004,,MD,CA,,EFAVIRENZ,Drug interaction;Psychiatric decompensation,214081321,OT,,,,,,,,,214081321,1,Depression
21408702,214087021,1,I,,20220926,20221004,20221004,EXP,,CA-AstraZeneca-2022A330151,ASTRAZENECA,,54,YR,,M,Y,,,20221004,,MD,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214087021,HO,,,,,,,,,214087021,1,Depression
21408781,214087811,1,I,20160101,20220927,20221004,20221004,EXP,,CN-GSK-CN2022APC138426,GLAXOSMITHKLINE,,,,,,Y,,,20221004,,HP,CN,CN,EFAVIRENZ,Ascites;Cholecystitis;Cholelithiasis;Collateral circulation;Faeces discoloured;Haemoglobin decreased;Hepatic cirrhosis;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Portal vein embolism;Splenomegaly;Varices oesophageal,214087811,OT,,,214087811,1,2015,,,,214087811,1,HIV infection
21408782,214087821,1,I,20160101,20220927,20221004,20221004,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC138426,VIIV,,,,,,Y,,,20221004,,HP,CN,CN,EFAVIRENZ,Ascites;Cholecystitis;Cholelithiasis;Collateral circulation;Faeces discoloured;Haemoglobin decreased;Hepatic cirrhosis;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Portal vein embolism;Splenomegaly;Varices oesophageal,214087821,OT,,,214087821,1,2015,,,,214087821,1,HIV infection
21409265,214092651,1,I,20210101,20220927,20221004,20221004,EXP,,CN-GSK-CN2022GSK141511,GLAXOSMITHKLINE,,,,,,Y,,,20221004,,HP,CN,CN,EFAVIRENZ,Abdominal distension;Abdominal pain;Bile duct stent insertion;Bile duct stone;Biliary dilatation;Duodenal ulcer;Hepatic mass;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Post cholecystectomy syndrome;Splenomegaly;Varices oesophageal,214092651,OT,,,214092651,1,2019,,,,214092651,1,HIV infection
21409266,214092661,1,I,20210101,20220927,20221004,20221004,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK141511,VIIV,,,,,,Y,,,20221004,,HP,CN,CN,EFAVIRENZ,Abdominal distension;Abdominal pain;Bile duct stent insertion;Bile duct stone;Biliary dilatation;Duodenal ulcer;Hepatic mass;Non-cirrhotic portal hypertension;Platelet count decreased;Portal hypertensive gastropathy;Post cholecystectomy syndrome;Splenomegaly;Varices oesophageal,214092661,OT,,,214092661,1,2019,,,,214092661,1,HIV infection
21411094,214110941,1,I,20160101,20220927,20221005,20221005,EXP,,CN-GILEAD-2022-0599697,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/j.issn.1001-5256.2022.09.028",46,YR,A,M,Y,,,20221005,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214110941,OT,,,214110941,1,2015,,,,214110941,1,HIV infection
21411176,214111761,1,I,20160101,20220927,20221005,20221005,EXP,,CN-GILEAD-2022-0600272,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/ j. issn.1001 -5256. 2022. 09. 028",40,YR,A,M,Y,,,20221005,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214111761,OT,,,214111761,1,2013,,,,214111761,1,HIV infection
21411267,214112671,1,I,20200101,20220927,20221005,20221005,EXP,,CN-GILEAD-2022-0600274,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/ j. issn.1001 -5256. 2022. 09. 028",67,YR,E,F,Y,,,20221005,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214112671,OT,,,214112671,1,2015,,,,214112671,1,HIV infection
21411370,214113701,1,I,20210101,20220927,20221005,20221005,EXP,,CN-GILEAD-2022-0600275,GILEAD,"Zhang L, Hu J, Gou C, Lv W. Analysis of the clinical characteristics of 6 cases of HIV mono-infected patients with noncirrhotic portal hypertension. J Clin Hepatol. 2022;38:unk. doi:10.3969/ j. issn.1001 -5256. 2022. 09. 028",43,YR,A,M,Y,,,20221005,,HP,CN,CN,EFAVIRENZ,Portal hypertension,214113701,OT,,,214113701,1,2019,,,,214113701,1,HIV infection
21411508,214115081,1,I,20160101,20220927,20221005,20221005,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK140964,VIIV,,,,,,Y,,,20221005,,HP,CN,CN,EFAVIRENZ,Cholecystitis chronic;Chronic gastritis;Faeces discoloured;Gastric varices;Haemoglobin decreased;Hepatic lesion;Non-cirrhotic portal hypertension;Renal cyst;Splenic fibrosis;Splenomegaly,214115081,HO,,,214115081,1,2013,,,,214115081,1,HIV infection
21411511,214115111,1,I,20160101,20220927,20221005,20221005,EXP,,CN-GSK-CN2022GSK140964,GLAXOSMITHKLINE,,,,,,Y,,,20221005,,HP,CN,CN,EFAVIRENZ,Cholecystitis chronic;Chronic gastritis;Faeces discoloured;Gastric varices;Haemoglobin decreased;Hepatic lesion;Non-cirrhotic portal hypertension;Renal cyst;Splenic fibrosis;Splenomegaly,214115111,OT,,,214115111,1,2013,,,,214115111,1,HIV infection
21411803,214118033,3,F,,20221101,20221005,20221110,EXP,,CA-MYLANLABS-2022M1110802,MYLAN,,54,YR,,M,Y,,,20221110,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214118033,OT,,,,,,,,,214118033,1,Bipolar disorder
21412002,214120022,2,F,,20221011,20221005,20221025,EXP,,"IN-LANNETT COMPANY, INC.-IN-2022LAN000170",LANNETT,,,,I,,Y,,,20221025,,CN,IN,IN,EFAVIRENZ,Neural tube defect,214120022,OT,,,,,,,,,214120022,1,Product used for unknown indication
21412923,214129232,2,F,20200801,20221005,20221005,20221012,EXP,,DK-GILEAD-2022-0600376,GILEAD,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Emergence of the G118R Pan-Integrase. 2022;14 (4):501-504. doi:10.3390/idr14040053",50,YR,A,M,Y,,,20221012,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,214129232,OT,,,,,,,,,214129232,1,HIV infection
21415835,214158351,1,I,,20220923,20221006,20221006,EXP,,US-AUROBINDO-AUR-APL-2022-040323,AUROBINDO,,,,I,,Y,,,20221006,,HP,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,214158351,OT,,,,,,,,,214158351,1,HIV infection
21415969,214159692,2,F,,20221011,20221006,20221020,EXP,,IN-CIPLA LTD.-2022IN05833,CIPLA,,,,N,,Y,,,20221020,,HP,IN,IN,EFAVIRENZ,Foetal exposure during pregnancy;Neural tube defect,214159692,CA,,,,,,,,,,,
21418024,214180242,2,F,,20221020,20221006,20221025,EXP,,JP-GSK-JP2022141732,GLAXOSMITHKLINE,,,,,,Y,,,20221025,,PH,JP,JP,EFAVIRENZ,Renal impairment,214180242,OT,,,,,,,,,214180242,1,HIV infection
21418037,214180372,2,F,,20221020,20221006,20221025,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022141732,VIIV,,,,,,Y,,,20221025,,PH,JP,JP,EFAVIRENZ,Renal impairment,214180372,OT,,,,,,,,,214180372,1,HIV infection
21419290,214192902,2,F,,20221011,20221006,20221021,EXP,,US-TEVA-2022-US-2078748,TEVA,,,,A,F,Y,,,20221021,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder;Treatment failure,214192902,OT,,,214192902,1,,,96,MON,214192902,1,HIV infection
21419292,214192922,2,F,,20221010,20221006,20221019,EXP,,DK-TEVA-2022-DK-2079789,TEVA,,50,YR,A,M,Y,,,20221019,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Treatment noncompliance,214192922,OT,,,,,,,,,214192922,1,HIV infection
21420561,214205612,2,F,,20221011,20221007,20221020,EXP,,IN-MACLEODS PHARMA EU LTD-MAC2022037552,MACLEODS,,,,,,Y,,,20221019,,HP,IN,IN,EFAVIRENZ,Anencephaly;Foetal exposure during pregnancy;Neural tube defect;Spina bifida,214205612,OT,,,,,,,,,214205612,1,Product used for unknown indication
21423307,214233071,1,I,,20221005,20221007,20221007,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2022EME137684,VIIV,,,,,,Y,,,20221007,,MD,FR,FR,SUSTIVA,Cerebral venous thrombosis;Logorrhoea;Vascular dementia;Vertigo;White matter lesion,214233071,HO,,,214233071,1,20210414,,,,214233071,1,HIV infection
21435862,214358621,1,I,20200101,20220927,20221010,20221010,EXP,,CN-GSK-CN2022GSK141118,GLAXOSMITHKLINE,,,,,,Y,,,20221010,,HP,CN,CN,EFAVIRENZ,Abdominal pain;Adrenal adenoma;Aspartate aminotransferase increased;Biliary dilatation;Collateral circulation;Duodenal ulcer;Gastric varices;Gastritis erosive;Haematemesis;Haemoglobin decreased;Hepatic cirrhosis;Intra-abdominal fluid collection;Non-cirrhotic portal hypertension;Pancreatic duct dilatation;Pelvic fluid collection;Platelet count decreased;Portal hypertensive gastropathy;Splenomegaly;Varices oesophageal,214358621,OT,,,214358621,1,2015,,,,214358621,1,HIV infection
21435863,214358631,1,I,20200101,20220927,20221010,20221010,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK141118,VIIV,,,,,,Y,,,20221010,,HP,CN,CN,EFAVIRENZ,Abdominal pain;Adrenal adenoma;Aspartate aminotransferase increased;Biliary dilatation;Collateral circulation;Duodenal ulcer;Gastric varices;Gastritis erosive;Haematemesis;Haemoglobin decreased;Hepatic cirrhosis;Intra-abdominal fluid collection;Non-cirrhotic portal hypertension;Pancreatic duct dilatation;Pelvic fluid collection;Platelet count decreased;Portal hypertensive gastropathy;Splenomegaly;Varices oesophageal,214358631,HO,,,214358631,1,2015,,,,214358631,1,HIV infection
21437515,214375151,1,I,,20220926,20221011,20221011,EXP,,DK-AUROBINDO-AUR-APL-2022-040749,AUROBINDO,"Mens H, Fjordside L, Fonager J, Gerstoft J.. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Infect-Dis-Rep. 2022;14(4):501-504.",50,YR,,M,Y,,,20221011,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance,214375151,OT,,,,,,,,,214375151,1,HIV infection
21439002,214390021,1,I,20210618,20221003,20221011,20221011,EXP,,ES-MYLANLABS-2022M1096222,MYLAN,,22,YR,,M,Y,,,20221011,,MD,ES,ES,EFAVIRENZ,Off label use;Treatment noncompliance;Virologic failure,214390021,OT,,,214390021,2,20210618,20220218,246,DAY,214390021,1,HIV infection
21441301,214413011,1,I,,20220510,20221011,20221011,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-045768,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20221011,,HP,CA,CA,SUSTIVA,Death,214413011,DE,,,,,,,,,214413011,1,HIV infection
21442302,214423022,2,F,,20221025,20221011,20221028,EXP,,AU-GILEAD-2022-0600776,GILEAD,,,,A,F,Y,,,20221028,,CN,AU,AU,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Depression;Diabetes mellitus;Lipodystrophy acquired,214423022,OT,,,214423022,1,2000,2017,,,214423022,1,HIV infection
21445128,214451282,2,F,,20221101,20221012,20221102,EXP,,IN-BAYER-2022A137744,BAYER,Kachhwaha A; Rohila AK; Tripathi S; Meena DS; Khichar S; Kumar D. Acute Myocardial Infarction in Hemophilia A with HIV and Hyperhomo-cysteinemia-A Rare Case Report. Cardiovascular and Hematological Disorders - Drug Targets. 2022;22:1:3-5,42,YR,A,M,Y,,,20221102,,HP,IN,IN,EFAVIRENZ,Acute myocardial infarction,214451282,HO,,,,,,,,,214451282,1,Joint swelling
21445143,214451431,1,I,,20221004,20221012,20221012,EXP,,IN-MYLANLABS-2022M1112866,MYLAN,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. India-J-Sex-Transm-Dis 2020;41(1):113-115.",,,,M,Y,,,20221012,,MD,IN,IN,EFAVIRENZ,Bipolar I disorder;Psychotic symptom,214451431,OT,,,,,,,,,214451431,1,HIV infection
21446472,214464721,1,I,,20221004,20221012,20221012,PER,,IN-LUPIN LIMITED-2022-11863,LUPIN,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. Indian Journal of Sexually Transmitted Diseases and AIDS. 2020;41:1:113-115",,,,M,Y,,,20221012,,HP,IN,IN,EFAVIRENZ,Therapy non-responder,214464721,OT,,,,,,,,,214464721,1,Bipolar I disorder
21449775,214497751,1,I,,20221004,20221013,20221013,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP013319,STRIDES,"Das S, Bhatia P.. Treatment non-responsiveness in depression following Efavirenz administration.. India-J-Sex-Transm-Dis. 2020;41(1):113-115",,,,M,Y,,,20221013,,MD,IN,IN,EFAVIRENZ,Bipolar I disorder;Condition aggravated;Psychotic symptom,214497751,OT,,,,,,,,,214497751,1,HIV infection
21454326,214543261,1,I,20120101,20221010,20221013,20221013,EXP,,PT-GILEAD-2022-0601266,GILEAD,,64,YR,A,M,Y,,,20221013,,MD,PT,PT,EFAVIRENZ,Headache;Hepatic steatosis;Hepatitis C;Insomnia;Magnetic resonance elastography;Malaise;Medication error;Treatment noncompliance,214543261,OT,,,214543261,1,202012,202012,12,WK,214543261,1,HIV infection
21454509,214545091,1,I,,20221011,20221013,20221013,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-119966,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20221014,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214545091,HO,,,,,,,,,214545091,1,HIV infection
21463825,214638251,1,I,,20220628,20221017,20221017,PER,,US-AUROBINDO-AUR-APL-2022-024680,AUROBINDO,,,,,,Y,,,20221017,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Product dispensing issue,,,,,,,,,,,214638251,1,Product used for unknown indication
21464395,214643951,1,I,,20221005,20221017,20221017,EXP,,US-CIPLA LTD.-2022US06095,CIPLA,"Boyce CL, Frenkel LM, Beck IA, Styrchak SM, Hardy SR, Wallner JJ et al.. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS ONE. 2022;17(9): e0275254:1 to 10",,,A,F,Y,,,20221017,,HP,US,US,EFAVIRENZ,Drug resistance;Exposure during pregnancy;No adverse event,214643951,OT,,,214643951,1,,,30,DAY,214643951,1,HIV infection
21464396,214643961,1,I,,20221005,20221017,20221017,EXP,,US-CIPLA LTD.-2022US06096,CIPLA,"Boyce CL, Frenkel LM, Beck IA, Styrchak SM, Hardy SR, Wallner JJ et al.. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS ONE. 2022;17 (9):1 to 10",,,,F,Y,,,20221017,,HP,US,US,EFAVIRENZ,Drug resistance;Exposure during pregnancy;No adverse event,214643961,OT,,,214643961,1,,,99,DAY,214643961,1,HIV infection
21465026,214650262,2,F,,20221016,20221017,20221026,EXP,,CA-TEVA-2022-CA-2816836,TEVA,,54,YR,A,M,Y,,,20221026,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214650262,OT,,,,,,,,,214650262,1,HIV infection
21465069,214650691,1,I,20090101,20221010,20221017,20221017,EXP,,PT-GSK-PT2022EME146428,GLAXOSMITHKLINE,,,,,,Y,,,20221017,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,214650691,OT,,,214650691,4,2022,,,,214650691,1,Product used for unknown indication
21466450,214664501,1,I,,20221007,20221017,20221017,EXP,,CA-TEVA-2022-CA-2816840,TEVA,,54,YR,A,M,Y,,,20221017,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,214664501,OT,,,,,,,,,214664501,1,HIV infection
21466648,214666481,1,I,,20221007,20221017,20221017,EXP,,CA-TEVA-2022-CA-2816834,TEVA,,54,YR,A,M,Y,,,20221017,,HP,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,214666481,OT,,,,,,,,,214666481,1,Depression
21467853,214678531,1,I,,20221009,20221017,20221017,EXP,,CN-GSK-CN2022APC144715,GLAXOSMITHKLINE,,,,,,Y,,,20221017,,MD,CN,CN,EFAVIRENZ,Acute kidney injury;Back pain;Chromaturia;Face oedema;Myalgia;Oedema;Oedema peripheral;Rhabdomyolysis,214678531,OT,,,,,,,,,214678531,1,HIV infection
21467856,214678561,1,I,,20221009,20221017,20221017,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC144715,VIIV,,,,,,Y,,,20221017,,MD,CN,CN,EFAVIRENZ,Acute kidney injury;Back pain;Chromaturia;Face oedema;Myalgia;Oedema;Oedema peripheral;Rhabdomyolysis,214678561,HO,,,,,,,,,214678561,1,HIV infection
21474222,214742221,1,I,20220101,20221012,20221018,20221018,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2022GSK146995,VIIV,"Ortiz-Martinez Y, Cabeza-Ruiz LD, Henao-Martinez AF, Rodriguez-Morales AJ. Clinical challenges of managing advanced AIDS in the tropics: Histoplasmosis, COVID-19, and shigellosis coinfections. New Microbes and New Infections. 2022;49-50",,,,,Y,,,20221018,,HP,CO,CO,EFAVIRENZ,Abdominal pain;Abdominal tenderness;Anaemia;Bronchiectasis;COVID-19;Cachexia;Chills;Cough;Diarrhoea;Dyspnoea;Hepatomegaly;Histoplasmosis;Hypertransaminasaemia;Hypoalbuminaemia;Hypoxia;Leukopenia;Lung consolidation;Lung opacity;Lymphopenia;Night sweats;Pulmonary septal thickening;Pyrexia;Rales;Shigella infection;Tachycardia;Treatment noncompliance;Virologic failure;Wheezing,214742221,OT,,,,,,,,,214742221,1,HIV infection
21478900,214789001,1,I,,20221014,20221019,20221019,EXP,,US-GILEAD-2022-0601923,GILEAD,,53,YR,A,M,Y,,,20221019,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Necrosis,214789001,OT,,,214789001,3,2020,,,,214789001,1,HIV infection
21485943,214859431,1,I,,20221011,20221020,20221020,EXP,,GB-MYLANLABS-2022M1115278,MYLAN,"Malaba TR, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H, et al. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet-HIV 2022;9(8):e534-e543.",,,A,F,Y,,,20221020,,HP,GB,GB,EFAVIRENZ,Hepatic cirrhosis;Maternal exposure during pregnancy,214859431,OT,,,,,,,,,214859431,1,HIV infection
21487384,214873841,1,I,20100629,20221011,20221020,20221020,EXP,,US-009507513-2210GBR007626,MERCK,,43,YR,,F,Y,,,20221020,,HP,US,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Exposure during pregnancy;Hepatic cytolysis;Intentional product use issue;Off label use,214873841,CA,,,214873841,1,20171006,20180205,4,MON,214873841,1,HIV infection
21496247,214962471,1,I,,20221010,20221022,20221022,EXP,,IN-AUROBINDO-AUR-APL-2022-044158,AUROBINDO,"Das S, Bhatia P. Treatment non-responsiveness in depression following Efavirenz administration. Indian Journal of Sexually Transmitted Diseases and AIDS Volume. 2020;41(1):113-115",23,YR,,M,Y,,,20221022,,MD,IN,IN,EFAVIRENZ,Abnormal behaviour;Bipolar disorder;Crying;Decreased appetite;Depressed mood;Depression;Insomnia;Social problem,214962471,OT,,,,,,,,,214962471,1,HIV infection
21497142,214971421,1,I,20211116,20221012,20221023,20221023,EXP,,MM-JNJFOC-20221022559,JOHNSON AND JOHNSON,,44,YR,A,F,Y,45,KG,20221023,,MD,MM,MM,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia of chronic disease;Bone tuberculosis;Cholelithiasis;Constipation;Depressed mood;Electrocardiogram QT prolonged;Hepatitis;Insomnia;Intentional product use issue;Off label use;Respiratory failure,214971421,HO,,,214971421,1,20210831,202109,216,DAY,214971421,1,Tuberculosis
21499877,214998771,1,I,,20221019,20221024,20221024,EXP,,CA-BAUSCH-BL-2022-023937,BAUSCH AND LOMB,,54,YR,,M,Y,,,20221024,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,214998771,HO,,,,,,,,,214998771,1,Product used for unknown indication
21500184,215001841,1,I,,20221019,20221024,20221024,EXP,,CA-BAUSCH-BL-2022-023960,BAUSCH AND LOMB,,54,YR,,M,Y,,,20221024,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration,215001841,OT,,,,,,,,,215001841,1,Product used for unknown indication
21501974,215019741,1,I,20090101,20221018,20221025,20221025,EXP,,PT-ABBVIE-4167335,ABBVIE,,,,,F,Y,,,20221025,,MD,PT,PT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215019741,OT,,,215019741,2,2022,,,,215019741,1,Product used for unknown indication
21507281,215072811,1,I,,20221019,20221026,20221026,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK153414,VIIV,,,,,,Y,,,20221026,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration,215072811,OT,,,,,,,,,215072811,1,Product used for unknown indication
21507282,215072821,1,I,,20221019,20221026,20221026,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK153360,VIIV,,,,,,Y,,,20221026,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215072821,HO,,,,,,,,,215072821,1,HIV infection
21507298,215072981,1,I,,20221019,20221026,20221026,EXP,,CA-GSK-CA2022GSK153360,GLAXOSMITHKLINE,,,,,,Y,,,20221026,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215072981,OT,,,,,,,,,215072981,1,HIV infection
21507299,215072991,1,I,,20221019,20221026,20221026,EXP,,CA-GSK-CA2022GSK153414,GLAXOSMITHKLINE,,,,,,Y,,,20221026,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration,215072991,OT,,,,,,,,,215072991,1,Product used for unknown indication
21507379,215073791,1,I,,20220607,20221026,20221026,EXP,,US-GSK-NA2022152666,GLAXOSMITHKLINE,,,,,,Y,,,20221026,,HP,US,,EFAVIRENZ,Drug resistance,215073791,OT,,,,,,,,,215073791,1,HIV infection
21507380,215073801,1,I,,20220607,20221026,20221026,EXP,,US-VIIV HEALTHCARE LIMITED-NA2022152666,VIIV,,,,,,Y,,,20221026,,HP,US,,EFAVIRENZ,Drug resistance,215073801,OT,,,,,,,,,215073801,1,HIV infection
21508316,215083163,3,F,20171006,20221025,20221026,20221104,EXP,,GB-ABBVIE-4173477,ABBVIE,,16,WK,,M,Y,,,20221104,,HP,GB,GB,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,215083163,CA,,,215083163,1,20100610,20100610,525,DAY,215083163,1,Maternal exposure timing unspecified
21512650,215126502,2,F,20090101,20221102,20221027,20221113,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-123975,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20221114,,MD,PT,PT,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215126502,OT,,,215126502,13,2022,,,,215126502,1,HIV infection
21514314,215143141,1,I,20090101,20221020,20221027,20221027,EXP,,NVSC2022PT236431,NOVARTIS,,,,,F,Y,,,20221027,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215143141,OT,,,215143141,13,2022,,,,215143141,1,Product used for unknown indication
21516294,215162941,1,I,20090101,20221020,20221027,20221027,EXP,,"PT-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-198370",BOEHRINGER INGELHEIM,,,,,F,Y,,,20221027,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215162941,OT,,,215162941,13,2022,,,,215162941,1,Product used for unknown indication
21516322,215163221,1,I,20090101,20221020,20221027,20221027,EXP,,PT-BAUSCHBL-2022BNL001296,BAUSCH AND LOMB,,,,,F,Y,,,20221027,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215163221,OT,,,215163221,13,2022,,,,215163221,1,Product used for unknown indication
21518479,215184791,1,I,20220401,20221020,20221028,20221028,EXP,,RU-HETERO-HET2022RU02643,HETERO,,21,YR,,M,Y,68,KG,20221028,,MD,RU,RU,EFAVIRENZ,Asthenia;Mental impairment;Sleep disorder;Somnolence,215184791,OT,,,215184791,1,20220404,20220516,43,DAY,215184791,1,HIV infection
21519822,215198221,1,I,20220828,,20221027,20221027,DIR,FDA-CDER-CTU-2022-86114,,FDA-CTU,,65,YR,,F,N,50,KG,20221021,N,HP,US,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Fanconi syndrome,215198221,HO,215198221,HP,215198221,1,20210715,20220829,,,215198221,1,HIV infection
21520696,215206961,1,I,20090101,20221021,20221028,20221028,EXP,,PT-PFIZER INC-202201256052,PFIZER,,,,,F,Y,,,20221028,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Myalgia;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215206961,DS,,,215206961,12,2022,,,,215206961,5,HIV infection
21521191,215211911,1,I,20090101,20221020,20221028,20221028,EXP,,PT-AstraZeneca-2022A351267,ASTRAZENECA,,,,,F,Y,,,20221028,,MD,PT,,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215211911,OT,,,215211911,11,2022,,,,215211911,1,Product used for unknown indication
21522098,215220983,3,F,,20221202,20221028,20221230,EXP,,GB-ABBVIE-4178626,ABBVIE,,,,,M,Y,,,20221230,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,215220983,OT,,,,,,,,,215220983,1,Maternal exposure timing unspecified
21524724,215247241,1,I,20090101,20221018,20221030,20221030,EXP,,PT-AUROBINDO-AUR-APL-2022-044879,AUROBINDO,,,,,F,Y,,,20221030,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215247241,OT,,,215247241,5,2022,,,,215247241,1,HIV infection
21527023,215270231,1,I,,20221018,20221031,20221031,EXP,,IN-CIPLA LTD.-2022IN06311,CIPLA,"Lad SG, Pandey V, Kolhe K, Chauhan S, Gattani M, Sethiya P et.al. AIH in HIV: A Very Much Possible Entity. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY. 2022;12 (5):1388 to 1392",48,YR,,F,Y,,,20221031,,HP,IN,IN,EFAVIRENZ,Acute on chronic liver failure;Anaemia;Autoimmune hepatitis;Gastric disorder;Hepatic cirrhosis;Nephropathy toxic;Portal hypertension;Thrombocytopenia;Varices oesophageal,215270231,OT,,,,,,,,,215270231,1,HIV infection
21532531,215325311,1,I,,20221018,20221101,20221101,EXP,,IN-CIPLA (EU) LIMITED-2022IN06312,CIPLA,"Lad SG, Pandey V, Kolhe K, Chauhan S, Gattani M, Sethiya P et.al. AIH in HIV: A Very Much Possible Entity. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY. 2022;12 (5):1388 to 1392",42,YR,,F,Y,,,20221101,,HP,IN,IN,EFAVIRENZ,Autoimmune hepatitis;Drug-induced liver injury,215325311,OT,,,,,,,,,215325311,1,HIV infection
21533699,215336991,1,I,20220101,20221021,20221101,20221101,EXP,,PT-MYLANLABS-2022M1117902,MYLAN,,,,,F,Y,,,20221101,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215336991,OT,,,215336991,12,2022,,,,215336991,1,Product used for unknown indication
21539100,215391001,1,I,,20221020,20221102,20221102,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2022-12626,LUPIN,,,,,,Y,,,20221102,,CN,ZA,ZA,EFAVIRENZ,Depression;Hypertension;Renal failure,215391001,HO,,,,,,,,,215391001,1,Hypertension
21547636,215476361,1,I,,20221026,20221103,20221103,EXP,,CA-AstraZeneca-2022A358685,ASTRAZENECA,,54,YR,,M,Y,,,20221103,,MD,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215476361,HO,,,,,,,,,215476361,1,Depression
21548316,215483161,1,I,,20221026,20221103,20221103,EXP,,ET-MYLANLABS-2022M1120452,MYLAN,"Hirigo AT, Gutema S, Eifa A, Ketema W. Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE-Open-Med-Case-Rep 2022;null:null.",47,YR,,M,Y,,,20221103,,HP,ET,ET,EFAVIRENZ,Type 2 diabetes mellitus,215483161,OT,,,215483161,2,20140716,,,,215483161,1,HIV infection
21548902,215489022,2,F,,20221026,20221103,20221209,EXP,,CA-GILEAD-2022-0602814,GILEAD,,54,YR,A,M,Y,,,20221209,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215489022,HO,,,,,,,,,215489022,1,Product used for unknown indication
21549976,215499762,2,F,,20221209,20221103,20221216,EXP,,PL-BRISTOL-MYERS SQUIBB COMPANY-2022-128597,BRISTOL MYERS SQUIBB,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: case report. HIV and AIDS Review. 2017 Oct 13; 16(3): 198-203.doi:10.5114/hivar.2017.70947.",43,YR,A,M,Y,,,20221216,,HP,PL,PL,EFAVIRENZ,Diarrhoea;Myalgia;Nausea;Neuropsychiatric symptoms,215499762,HO,,,215499762,1,2011,,,,215499762,1,Acquired immunodeficiency syndrome
21552956,215529562,2,F,20170101,20221208,20221104,20221214,EXP,,US-GILEAD-2022-0603472,GILEAD,,47,YR,A,F,Y,108.84,KG,20221214,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Blood cholesterol increased;Blood glucose increased;Bone demineralisation;Depression;Emotional distress;Gait disturbance;Hypertension;Osteopenia;Osteoporosis;Pain;Type 2 diabetes mellitus,215529562,OT,,,215529562,1,2001,,,,215529562,1,HIV infection
21556331,215563312,2,F,20110101,20221128,20221104,20221208,EXP,,PL-TEVA-2022-PL-2821833,TEVA,,43,YR,A,M,Y,,,20221208,,HP,PL,PL,EFAVIRENZ,Acquired phimosis;Blood bilirubin increased;Clostridium difficile infection;Conductive deafness;Diarrhoea;Drug ineffective;Enterobacter infection;Hepatitis cholestatic;Hepatitis toxic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection,215563312,HO,,,215563312,5,201104,,4,MON,215563312,1,Candida infection
21557464,215574641,1,I,20110101,20221024,20221105,20221105,EXP,,PL-AUROBINDO-AUR-APL-2022-046649,AUROBINDO,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV-AIDSRev. 2017;16(3):198-203",43,YR,,M,Y,,,20221105,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Enterobacter infection;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis,215574641,HO,,,215574641,16,201112,,,,215574641,1,Enterobacter infection
21557666,215576662,2,F,,20221107,20221106,20221118,EXP,,PL-JNJFOC-20221056107,JOHNSON AND JOHNSON,,43,YR,A,M,Y,,,20221118,,HP,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,215576662,HO,,,215576662,2,2011,,,,215576662,1,Acquired immunodeficiency syndrome
21559678,215596781,1,I,,20221028,20221107,20221107,EXP,,PL-GSK-PL2022EME156810,GLAXOSMITHKLINE,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV-AIDS-Rev. 2017;16(3):198-203",,,,,Y,,,20221107,,MD,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract inflammation,215596781,OT,,,215596781,8,201112,,,,215596781,1,HIV infection
21559679,215596791,1,I,,20221028,20221107,20221107,EXP,,PL-VIIV HEALTHCARE LIMITED-PL2022EME156810,VIIV,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV-AIDS-Rev. 2017;16(3):198-203",,,,,Y,,,20221107,,MD,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract inflammation,215596791,OT,,,215596791,8,201112,,,,215596791,1,HIV infection
21561611,215616111,1,I,20221103,,20221104,20221104,DIR,637338,,FDA-CTU,,41,YR,,UNK,N,,,20221104,N,PH,US,,EFAVIRENZ,Somnolence,,,215616111,HP,215616111,1,20220330,20221102,,,215616111,1,HIV infection
21575629,215756291,1,I,,20221107,20221110,20221110,EXP,,CA-ROCHE-3214683,ROCHE,,54,YR,,M,Y,,,20221110,,HP,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,215756291,HO,,,,,,,,,215756291,1,Depression
21577372,215773721,1,I,20221018,20221103,20221110,20221110,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC159266,VIIV,,,,,,Y,,,20221110,,HP,CN,CN,EFAVIRENZ,Chromaturia;Drug-induced liver injury;Hyperbilirubinaemia;Jaundice;Mucocutaneous disorder;Ocular icterus;Yellow skin,215773721,HO,,,215773721,1,20221015,20221018,3,DAY,215773721,1,Antiviral treatment
21577560,215775601,1,I,,20221104,20221110,20221110,EXP,,IT-MYLANLABS-2022M1122353,MYLAN,"Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, et al. Alzheimer Dementia in People Living With HIV. Neurol-Clin-Pract. 2021;11(5):E627-E633",71,YR,,M,Y,,,20221110,,MD,IT,IT,EFAVIRENZ,Dementia Alzheimer's type,215775601,OT,,,,,,,,,215775601,1,HIV infection
21577958,215779581,1,I,,20221103,20221110,20221110,EXP,,IN-GSK-IN2022GSK159630,GLAXOSMITHKLINE,"Sil A, Bhanja DB, Panigrahi A, Biswas S. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian Journal of Dermatology. 2022;67(3):316",,,,,Y,,,20221110,,HP,IN,IN,EFAVIRENZ,Acanthosis;Epidermodysplasia verruciformis;Hyperkeratosis;Koebner phenomenon;Papilloma;Papule;Rash;Skin hypopigmentation;Skin lesion;Skin plaque,215779581,OT,,,,,,,,,215779581,1,HIV infection
21577960,215779601,1,I,,20221103,20221110,20221110,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK159630,VIIV,"Sil A, Bhanja DB, Panigrahi A, Biswas S. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian Journal of Dermatology. 2022;67(3):316",,,,,Y,,,20221110,,HP,IN,IN,EFAVIRENZ,Acanthosis;Epidermodysplasia verruciformis;Hyperkeratosis;Koebner phenomenon;Papilloma;Papule;Rash;Skin hypopigmentation;Skin lesion;Skin plaque,215779601,OT,,,,,,,,,215779601,1,HIV infection
21580770,215807702,2,F,,20221114,20221111,20221129,EXP,,PL-MACLEODS PHARMA EU LTD-MAC2022038181,MACLEODS,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzyszta?owski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV and AIDS Review. 2017;16(3):198-203",,,,,Y,,,20221128,,MD,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neutropenia;Pancreatitis;Phimosis;Urinary tract infection;Urinary tract inflammation,215807702,HO,,,215807702,23,,,21,DAY,215807702,1,Tuberculosis
21580772,215807721,1,I,20220101,20221104,20221111,20221111,EXP,,NVSC2022PT248996,NOVARTIS,,,,,F,Y,,,20221111,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215807721,OT,,,,,,,,,215807721,1,Product used for unknown indication
21582714,215827141,1,I,20220101,20221031,20221111,20221111,EXP,,ZM-CIPLA LTD.-2022ZM06539,CIPLA,"Kaweme NM, Mantina HM, Butress SNM. Long-Term Zidovudine Therapy and Whether It is a Trigger of Vitamin B12 Deficiency: A Case Study of Megaloblastic Anemia at the University of Zambia Teaching Hospital. Case Reports in Hematology. 2022;1 to 6",52,YR,,M,Y,,,20221111,,HP,ZM,ZM,EFAVIRENZ,Anaemia folate deficiency,215827141,HO,,,215827141,1,2017,,,,215827141,1,HIV infection
21583473,215834731,1,I,20150101,20221107,20221111,20221111,EXP,,PT-MYLANLABS-2022M1123746,MYLAN,,45,YR,,M,Y,,,20221111,,MD,PT,PT,EFAVIRENZ,Drug intolerance;Hepatitis C;Hyperhidrosis;Lipids abnormal;Nausea;Nervous system disorder;Palpitations;Weight fluctuation,215834731,OT,,,215834731,1,200307,201504,,,215834731,1,Antiretroviral therapy
21584078,215840783,3,F,20120521,20221123,20221111,20221202,EXP,,GB-EMD Serono-E2B_90051827,EMD SERONO INC,,3,MON,I,M,Y,,,20221202,,HP,GB,,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Off label use;Trisomy 18;Ultrasound antenatal screen,215840783,CA,,,,,,,,,215840783,1,Foetal exposure during pregnancy
21584097,215840971,1,I,,20221108,20221111,20221111,EXP,,CA-ROCHE-3215860,ROCHE,,54,YR,,M,Y,,,20221111,,HP,CA,,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration,215840971,OT,,,,,,,,,215840971,1,Product used for unknown indication
21585749,215857491,1,I,,20221104,20221111,20221111,EXP,,PT-AstraZeneca-2022A366132,ASTRAZENECA,,,,,F,Y,,,20221111,,MD,PT,,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215857491,OT,,,215857491,8,2022,,,,215857491,1,Product used for unknown indication
21593961,215939611,1,I,20110101,20221107,20221115,20221115,EXP,,PL-ZAMBON SWITZERLAND LTD.-2022PL000045,ZAMBON,"B.J. Aksak-Was, M.Leszczyszyn-Pynka, M. Parczewski, A.Krzysztalowski. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV and AIDS Review. 2017;16 (3):198-203",,,,,Y,,,20221115,,MD,PL,PL,EFAVIRENZ,Hepatitis cholestatic,215939611,HO,,,,,,,,,215939611,1,Urinary tract infection
21594096,215940961,1,I,,20221108,20221115,20221115,EXP,,IN-STRIDES ARCOLAB LIMITED-2022SP015194,STRIDES,"Sil A, Bhanja DB, Panigrahi A, Biswas SK.. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian-J-Dermatol. 2022;67(3)",42,YR,,M,Y,,,20221115,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,215940961,OT,,,,,,,,,215940961,1,HIV infection
21594243,215942432,2,F,20120101,20221114,20221115,20221128,EXP,,PL-AUROBINDO-AUR-APL-2022-047793,AUROBINDO,"Aksak-Was BJ, et al. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV and AIDS Review 16. 2017;No. 3:198-203",44,YR,,M,Y,,,20221128,,MD,PL,PL,EFAVIRENZ,Hepatitis cholestatic;Pancreatitis;Phimosis;Urinary tract infection,215942432,OT,,,215942432,19,2011,,,,215942432,1,Product used for unknown indication
21595476,215954761,1,I,20120101,20221107,20221115,20221115,EXP,,PL-ZAMBON SWITZERLAND LTD.-2022PL000046,ZAMBON,"B.J. Aksak-Was, M.Leszczyszyn-Pynka, M. Parczewski, A.Krzysztalowski. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV and AIDS Review. 2017;16 (3):198-203",,,,,Y,,,20221115,,MD,PL,PL,EFAVIRENZ ACCORD,Clostridium difficile infection;Pancreatitis,215954761,HO,,,,,,,,,215954761,1,Urinary tract infection
21596620,215966201,1,I,,20221101,20221115,20221115,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022GSK160027,VIIV,,,,,,Y,,,20221115,,HP,CN,CN,EFAVIRENZ,Pathogen resistance,215966201,OT,,,215966201,1,,,2,YR,215966201,1,HIV infection
21596621,215966211,1,I,,20221101,20221115,20221115,EXP,,CN-GSK-CN2022GSK160027,GLAXOSMITHKLINE,,,,,,Y,,,20221115,,HP,CN,CN,EFAVIRENZ,Pathogen resistance,215966211,OT,,,215966211,1,,,2,YR,215966211,1,HIV infection
21596656,215966561,1,I,,20221108,20221115,20221115,EXP,,IN-MYLANLABS-2022M1125136,MYLAN,"Sil A, Bhanja DB, Panigrahi A, Biswas SK. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian-J-Dermatol 2022;67:No. 3.",42,YR,,M,Y,,,20221115,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,215966561,OT,,,,,,,,,215966561,1,HIV infection
21599948,215999481,1,I,20220101,20221109,20221116,20221116,EXP,,PT-ABBVIE-4194907,ABBVIE,,,,,F,Y,,,20221116,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,215999481,OT,,,215999481,5,2022,,,,215999481,1,Product used for unknown indication
21601033,216010331,1,I,,20221107,20221116,20221116,EXP,,IN-CIPLA LTD.-2022IN06662,CIPLA,"Sil A, Bhanja DB, Panigrahi A, Biswas SK. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian J Dermatol. 2022;67(3):316",42,YR,,M,Y,,,20221116,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis,216010331,OT,,,,,,,,,216010331,1,HIV infection
21601075,216010751,1,I,20090101,20221104,20221116,20221116,EXP,,"PT-COLLEGIUM PHARMACEUTICAL, INC.-20221100404",COLLEGIUM PHARMACEUTICAL,,,,,,Y,,,20221116,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingival pain;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Tongue injury;Weight increased,216010751,OT,,,216010751,14,2022,,,,216010751,1,Product used for unknown indication
21601446,216014461,1,I,,20221103,20221116,20221116,EXP,,PL-AUROBINDO-AUR-APL-2022-047821,AUROBINDO,"Aksak-Was BJ, et al.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV and AIDS Review 16. 2017;No. 3:198-203",43,YR,,M,Y,,,20221116,,HP,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Hepatitis cholestatic;Pancreatitis,216014461,HO,,,,,,,,,216014461,1,Product used for unknown indication
21601543,216015431,1,I,20220101,20221102,20221116,20221116,EXP,,PT-AUROBINDO-AUR-APL-2022-047575,AUROBINDO,,,,,F,Y,,,20221116,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,216015431,OT,,,216015431,9,2022,,,,216015431,1,HIV infection
21602270,216022706,6,F,,20221212,20221116,20221219,EXP,,NVSC2022PL256627,NOVARTIS,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV AND AIDS REVIEW. 2017;16(3):198-203",43,YR,,M,Y,,,20221219,,HP,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216022706,HO,,,216022706,8,2011,,,,216022706,1,Toxoplasmosis
21606382,216063824,4,F,,20221209,20221117,20221223,EXP,,PL-AUROBINDO-AUR-APL-2022-047778,AUROBINDO,"Aksak-Was BJ, et al.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV and AIDS Review 16. 2017;3:198-203",43,YR,,M,Y,,,20221223,,MD,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216063824,HO,,,216063824,5,201112,,,,216063824,1,Urinary tract infection
21606481,216064811,1,I,,20221103,20221117,20221117,EXP,,PL-AUROBINDO-AUR-APL-2022-047762,AUROBINDO,"Aksak-Was BJ, et al. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV and AIDS Review 16. 2017;3:198-203",43,YR,,M,Y,,,20221117,,HP,PL,PL,EFAVIRENZ,Drug resistance,216064811,HO,,,,,,,,,216064811,1,Product used for unknown indication
21606753,216067533,3,F,,20221212,20221117,20221219,EXP,,PL-GILEAD-2022-0603189,GILEAD,"Aksak-W?s B.J., Leszczyszyn-Pynka M., Parczewski M., Krzyszta?owski A.. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV + AIDS Review. 2017;16(3):98-203. doi:https://doi.org/10.5114/hivar.2017.70947",43,YR,A,M,Y,,,20221219,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216067533,HO,,,216067533,4,2011,,,,216067533,1,HIV infection
21609769,216097691,1,I,20180101,20221103,20221117,20221117,EXP,,CN-GSK-CN2022APC160306,GLAXOSMITHKLINE,,,,,,Y,,,20221117,,MD,CN,CN,EFAVIRENZ,Alopecia;Amnesia;Hepatomegaly;Kidney enlargement;Mitochondrial cytopathy;Renal cyst;Therapy cessation,216097691,OT,,,216097691,1,201607,20180218,13,MON,216097691,1,HIV infection
21609774,216097741,1,I,20180101,20221103,20221117,20221117,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC160306,VIIV,,,,,,Y,,,20221117,,MD,CN,CN,EFAVIRENZ,Alopecia;Amnesia;Hepatomegaly;Kidney enlargement;Mitochondrial cytopathy;Renal cyst;Therapy cessation,216097741,OT,,,216097741,1,201607,20180218,13,MON,216097741,1,HIV infection
21615178,216151781,1,I,,20221110,20221118,20221118,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2022GSK165931,VIIV,"Koech MK, Ali SM, Karoney MJ, Kigen G. Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. Journal of medical case reports.. 2022;16(1):407",,,,,Y,,,20221118,,HP,KE,KE,EFAVIRENZ,Abdominal discomfort;Abdominal pain;Abdominal tenderness;Acute kidney injury;Blood HIV RNA increased;Chest discomfort;Chest pain;Chills;Confusional state;Conversion disorder;Cough;Decreased appetite;Diarrhoea;Generalised oedema;Headache;Hepatic function abnormal;Hepatitis viral;Hyperhidrosis;Hypersensitivity;Hypotension;Malaise;Myalgia;Nausea;Neuropathy peripheral;Nosocomial infection;Oropharyngeal pain;Pain;Palpitations;Paraesthesia;Pharyngeal inflammation;Pharyngitis;Pyrexia;Rash;Respiratory alkalosis;Self-medication;Stomatitis;Tachycardia;Virologic failure;Vomiting,216151781,HO,,,216151781,8,,,2,MON,216151781,1,HIV infection
21619349,216193491,1,I,,20221111,20221120,20221120,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-137995,BRISTOL MYERS SQUIBB,,62,YR,A,F,Y,43.09,KG,20221121,,CN,US,US,SUSTIVA,Amnesia;Arthritis;Arthropathy;Bipolar disorder;Bone disorder;Limb discomfort;Post-traumatic stress disorder;Renal disorder;Spinal fracture;Weight decreased,216193491,OT,,,216193491,1,1999,20220930,8673,DAY,216193491,1,HIV test positive
21624815,216248151,1,I,,20220502,20221122,20221122,EXP,,KE-ALKEM LABORATORIES LIMITED-KE-ALKEM-2022-04413,ALKEM,"Kipsang JK, Choge JK, Marinda PA, Khayeka-Wandabwa C. Pellagra in isoniazid preventive and antiretroviral therapy. IDCases. 2019;17:e00550",30,YR,,F,Y,,,20221122,,HP,KE,KE,EFAVIRENZ,Abdominal discomfort;Abdominal pain upper;Diarrhoea;Nicotinic acid deficiency;Odynophagia;Rash,,,,,216248151,1,20180104,,8,WK,216248151,1,Product used for unknown indication
21624820,216248201,1,I,,20220602,20221122,20221122,EXP,,UG-ALKEM LABORATORIES LIMITED-UG-ALKEM-2022-05899,ALKEM,"Nakiyingi L, Baluku JB, Ssengooba W, Namiiro SM, et.al. Recurrent pneumothorax in a human immunodeficiency virus-positive patient with multidrug-resistant tuberculosis: a rare case of bronchopleural fistula: a case report. J Med Case Rep. 2022;16:214",39,YR,,M,Y,,,20221122,,HP,UG,UG,EFAVIRENZ,Treatment failure,216248201,HO,,,,,,,,,216248201,1,Tuberculosis
21629659,216296591,1,I,20220101,20221109,20221122,20221122,EXP,,PT-ALLERGAN-2238320US,ALLERGAN,,,,,F,Y,,,20221122,,MD,PT,PT,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abnormal dreams;Alopecia;Anxiety;Arthralgia;Asthma;Bundle branch block left;Chronic obstructive pulmonary disease;Chronic respiratory disease;Condition aggravated;Confusional arousal;Degenerative bone disease;Dry mouth;Dyslipidaemia;Gastric disorder;Gastritis;Gingivitis;HIV infection;Helicobacter infection;Joint stiffness;Leukopenia;Middle insomnia;Mouth injury;Nasal polyps;Osteopenia;Osteoporosis;Pain;Paroxysmal extreme pain disorder;Peptic ulcer;Polymyalgia rheumatica;Post procedural hypothyroidism;Rhinitis allergic;Tinnitus;Tongue discomfort;Weight increased,216296591,OT,,,216296591,5,2022,,,,216296591,1,Product used for unknown indication
21630149,216301493,3,F,,20221128,20221122,20221213,EXP,,IN-GILEAD-2022-0604339,GILEAD,Sil A. Bhanja D. Panigrahi A. Biswas S. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian Journal of Dermatology.. 2022;67 (3):316. doi:10.4103/ijd.IJD_747_20,42,YR,A,M,Y,,,20221213,,HP,IN,IN,EFAVIRENZ,Drug ineffective;Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,216301493,OT,,,,,,,,,216301493,1,HIV infection
21634299,216342991,1,I,20190101,20220608,20221123,20221123,EXP,,RU-GSK-RU2022GSK164326,GLAXOSMITHKLINE,"Morgunova TB, Maloletkina ES, Amergulov II, Glinkina IV, Pavlova MG, Fadeyev VV. Panhypopituitarism in HIV patient receiving antiretroviral therapy. Russian Open Medical Journal. 2021;10(4)",,,,,Y,,,20221123,,MD,RU,RU,EFAVIRENZ,Androgen deficiency;Asthenia;Central hypothyroidism;Condition aggravated;Empty sella syndrome;Erectile dysfunction;Fatigue;Growth hormone deficiency;Hypopituitarism;Hypotrichosis;Libido decreased;Osteopenia;Performance status decreased;Secondary adrenocortical insufficiency;Secondary hypogonadism;Weight decreased,216342991,HO,,,,,,,,,216342991,1,HIV infection
21634300,216343001,1,I,20190101,20220608,20221123,20221123,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2022GSK164326,VIIV,"Morgunova TB, Maloletkina ES, Amergulov II, Glinkina IV, Pavlova MG, Fadeyev VV. Panhypopituitarism in HIV patient receiving antiretroviral therapy. Russian Open Medical Journal. 2021;10(4)",,,,,Y,,,20221123,,MD,RU,RU,EFAVIRENZ,Androgen deficiency;Asthenia;Central hypothyroidism;Condition aggravated;Empty sella syndrome;Erectile dysfunction;Fatigue;Growth hormone deficiency;Hypopituitarism;Hypotrichosis;Libido decreased;Osteopenia;Performance status decreased;Secondary adrenocortical insufficiency;Secondary hypogonadism;Weight decreased,216343001,OT,,,,,,,,,216343001,1,HIV infection
21636380,216363801,1,I,,20221110,20221124,20221124,EXP,,UG-CIPLA (EU) LIMITED-2022UG06732,CIPLA,"Kiggundu R, Nabeta HW, Okia R, Rhein J, Lukande R.. Unmasking histoplasmosis immune reconstitution inflammatory syndrome in a patient recently started on antiretroviral therapy. Autopsy and Case Reports. 2016;6 (4):27 to 33",43,YR,,M,Y,,,20221124,,HP,UG,UG,EFAVIRENZ,Histoplasmosis cutaneous;Immune reconstitution inflammatory syndrome,216363801,OT,,,,,,,,,216363801,1,HIV infection
21637260,216372601,1,I,,20221110,20221124,20221124,EXP,,PL-AUROBINDO-AUR-APL-2022-049150,AUROBINDO,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A... Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV-AIDS-Rev.. 2017;16(3):198-203",,,A,M,Y,,,20221124,,MD,PL,PL,EFAVIRENZ,Clostridium difficile colitis;Diarrhoea;Drug resistance;Hepatitis cholestatic;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract inflammation,216372601,OT,,,216372601,5,20200714,,,,216372601,1,Urinary tract inflammation
21644169,216441691,1,I,,20221118,20221125,20221125,EXP,,JP-GSK-JP2022JPN172504,GLAXOSMITHKLINE,Kashiwabara Y. TR5-2 A case of an AIDS patient with multiple drug-resistant mutant viruses whose dolutegravir was administered by simple suspension method and its blood concentration was measured. The 36th Annual Meeting of the Japanese Society for AIDS Research HIV Infectious. 2022,,,,,Y,,,20221125,,PH,JP,JP,EFAVIRENZ,Anaemia;Dysphagia;Gastrostomy;Hepatic function abnormal;Hypopharyngeal cancer stage II;Off label use;Pathogen resistance;Product use issue;Renal impairment,216441691,OT,,,,,,,,,216441691,1,Acquired immunodeficiency syndrome
21644170,216441701,1,I,,20221118,20221125,20221125,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022JPN172504,VIIV,Kashiwabara Y. TR5-2 A case of an AIDS patient with multiple drug-resistant mutant viruses whose dolutegravir was administered by simple suspension method and its blood concentration was measured. The 36th Annual Meeting of the Japanese Society for AIDS Research HIV Infectious. 2022,,,,,Y,,,20221125,,PH,JP,JP,EFAVIRENZ,Anaemia;Dysphagia;Gastrostomy;Hepatic function abnormal;Hypopharyngeal cancer stage II;Off label use;Pathogen resistance;Product use issue;Renal impairment,216441701,OT,,,,,,,,,216441701,1,Acquired immunodeficiency syndrome
21646702,216467021,1,I,,20221113,20221127,20221127,EXP,,CA-TEVA-2022-CA-2828583,TEVA,,54,YR,A,M,Y,,,20221126,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,216467021,HO,,,,,,,,,216467021,1,HIV infection
21646723,216467231,1,I,,20221114,20221127,20221127,EXP,,CA-TEVA-2022-CA-2828721,TEVA,,54,YR,A,M,Y,,,20221126,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration,216467231,OT,,,,,,,,,216467231,1,Product used for unknown indication
21647398,216473981,1,I,20170822,20220817,20221128,20221128,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022036934,MACLEODS,,,,,,Y,,,20221125,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,216473981,OT,,,216473981,1,20170224,,,,216473981,1,HIV infection
21649235,216492351,1,I,20120101,20221114,20221128,20221128,EXP,,PL-ACS-20220174,ACS DOBFAR,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV and AIDS Review. 2017;16(3:)198-203. DOI: 10.5114/HIVAR.2017.67788",44,YR,A,M,Y,,,20221115,,MD,PL,,EFAVIRENZ,Clostridium difficile colitis;Off label use;Pancreatitis,216492351,OT,,,216492351,1,2011,,21,DAY,216492351,1,Cytomegalovirus chorioretinitis
21649236,216492361,1,I,20120101,20221114,20221128,20221128,EXP,,PL-AUROBINDO-AUR-APL-2022-049088,AUROBINDO,"Aksak-Was BJ, Leszczyszyn-Pynka M, Parczewski M, Krzysztalowski A.. . Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report.. HIV and AIDS Review. 2017;16(3):198-203",44,YR,,M,Y,,,20221128,,MD,PL,PL,EFAVIRENZ,Lymphopenia;Neutropenia,216492361,OT,,,216492361,1,2012,,,,216492361,1,Urinary tract inflammation
21651342,216513421,1,I,,20221114,20221128,20221128,EXP,,PL-AUROBINDO-AUR-APL-2022-049669,AUROBINDO,"Aksak-Was BJ, et al. Interdisciplinary management of multidrug-resistant tuberculosis in an HIV-infected patient: Case report. HIV and AIDS Review. 2017;16:198-203",43,YR,,M,Y,,,20221128,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neutropenia;Pancreatitis;Urinary tract infection,216513421,HO,,,,,,,,,216513421,1,Product used for unknown indication
21652667,216526672,2,F,,20221122,20221128,20221219,EXP,,CA-MYLANLABS-2022M1132690,MYLAN,,52,YR,,M,Y,,,20221219,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,216526672,OT,,,,,,,,,216526672,1,HIV infection
21652898,216528981,1,I,,20221121,20221128,20221128,EXP,,JP-GSK-JP2022GSK177053,GLAXOSMITHKLINE,,,,,,Y,,,20221128,,HP,JP,JP,EFAVIRENZ,Altered state of consciousness;Aphasia;Central nervous system lesion;Cognitive disorder;Condition aggravated;Epilepsy;Hemiparesis;Immune reconstitution inflammatory syndrome;Inflammation;Meningitis cryptococcal;Sensory disturbance,216528981,OT,,,,,,,,,216528981,1,HIV infection
21652900,216529001,1,I,,20221121,20221128,20221128,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022GSK177053,VIIV,,,,,,Y,,,20221128,,HP,JP,JP,EFAVIRENZ,Altered state of consciousness;Aphasia;Central nervous system lesion;Cognitive disorder;Condition aggravated;Epilepsy;Hemiparesis;Immune reconstitution inflammatory syndrome;Inflammation;Meningitis cryptococcal;Sensory disturbance,216529001,OT,,,,,,,,,216529001,1,HIV infection
21654524,216545242,2,F,,20221205,20221129,20221219,EXP,,IN-AUROBINDO-AUR-APL-2022-050424,AUROBINDO,"Sil A, Bhanja DB, Panigrahi A, Biswas SK.. Acquired epidermodysplasia verruciformis during highly active antiretroviral therapy. Indian-J-Dermatol. 2022;67No. 3.:316",42,YR,,M,Y,,,20221219,,HP,IN,IN,EFAVIRENZ,Epidermodysplasia verruciformis;Immune reconstitution inflammatory syndrome,216545242,OT,,,,,,,,,216545242,1,HIV infection
21657119,216571191,1,I,,20221121,20221129,20221129,EXP,,CA-MYLANLABS-2022M1132947,MYLAN,,54,YR,,M,Y,,,20221129,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,216571191,OT,,,,,,,,,216571191,1,Bipolar disorder
21660043,216600431,1,I,,20221121,20221130,20221130,EXP,,CA-APOTEX-2022AP015893,APOTEX,,63,YR,,F,Y,,,20221130,,CN,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,216600431,OT,,,,,,,,,216600431,1,HIV infection
21666597,216665971,1,I,,20221121,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06920,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216665971,OT,,,,,,,,,216665971,1,HIV infection
21666598,216665981,1,I,,20221121,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06918,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216665981,OT,,,,,,,,,216665981,1,HIV infection WHO clinical stage I
21666604,216666041,1,I,,20221121,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06922,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216666041,OT,,,,,,,,,216666041,1,HIV infection WHO clinical stage III
21666705,216667051,1,I,,20221121,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06919,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216667051,OT,,,,,,,,,216667051,1,HIV infection WHO clinical stage I
21666706,216667061,1,I,,20221121,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06916,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes.. AIDS. 2021;35 (10):1597 to 1604",,,,F,Y,,,20221201,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216667061,OT,,,,,,,,,216667061,1,HIV infection
21666707,216667071,1,I,,20221121,20221201,20221201,EXP,,ZA-CIPLA LTD.-2022ZA06921,CIPLA,"Millar JR, Goulder P, Fatti I, Mchunu N, Bengu N, Grayson NE et al.. Second-generation mother-to-child HIV transmission in South Africa is characterized by poor outcomes. AIDS. 2021;35 (10):1597 to 1604",18,YR,,F,Y,,,20221201,,HP,ZA,ZA,EFAVIRENZ,Treatment failure,216667071,OT,,,,,,,,,216667071,1,HIV infection WHO clinical stage I
21668271,216682711,1,I,,20221121,20221201,20221201,EXP,,TW-GSK-TW2022APC173392,GLAXOSMITHKLINE,Chong YB. Immune reconstitution inflammatory syndrome: case report. Adis Insight. 2022,,,,,Y,,,20221201,,HP,TW,TW,EFAVIRENZ,Abscess limb;Adrenal neoplasm;Epstein-Barr virus infection;Extradural neoplasm;Febrile neutropenia;Hypoaesthesia;Immune reconstitution inflammatory syndrome;Leiomyoma;Malaise;Paraplegia;Schwannoma;Septic shock;Smooth muscle cell neoplasm;Spinal cord compression;Spinal cord neoplasm,216682711,OT,,,,,,,,,216682711,1,HIV infection
21668329,216683291,1,I,,20221121,20221201,20221201,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2022APC173392,VIIV,Chong YB. Immune reconstitution inflammatory syndrome: case report. Adis Insight. 2022,,,,,Y,,,20221201,,HP,TW,TW,EFAVIRENZ,Abscess limb;Adrenal neoplasm;Epstein-Barr virus infection;Extradural neoplasm;Febrile neutropenia;Hypoaesthesia;Immune reconstitution inflammatory syndrome;Leiomyoma;Malaise;Paraplegia;Schwannoma;Septic shock;Smooth muscle cell neoplasm;Spinal cord compression;Spinal cord neoplasm,216683291,OT,,,,,,,,,216683291,1,HIV infection
21670133,216701331,1,I,,20221130,20221201,20221201,EXP,,CA-BAUSCH-BL-2022-026430,BAUSCH AND LOMB,,54,YR,,M,Y,,,20221201,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,216701331,DE,,,,,,,,,216701331,1,Bipolar disorder
21675341,216753411,1,I,,20221128,20221202,20221202,EXP,,JP-GSK-JP2022JPN178225,GLAXOSMITHKLINE,Kanai O. Review of two cases of cerebrovascular events in young HIV-positive patients despite low risk of lifestyle disease. The Journal of AIDS Research/The 36th Annual Meeting of the Japanese Society for. 2022;24 (4):459(335),,,,,Y,,,20221202,,MD,JP,JP,EFAVIRENZ,Altered state of consciousness;Diplopia;Dysarthria;Hemiparesis;Sensory disturbance;Thrombotic cerebral infarction,216753411,HO,,,,,,,,,216753411,1,HIV infection
21675344,216753441,1,I,,20221128,20221202,20221202,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022JPN178225,VIIV,Kanai O. Review of two cases of cerebrovascular events in young HIV-positive patients despite low risk of lifestyle disease. The Journal of AIDS Research/The 36th Annual Meeting of the Japanese Society for. 2022;24 (4):459(335),,,,,Y,,,20221202,,MD,JP,JP,EFAVIRENZ,Altered state of consciousness;Diplopia;Dysarthria;Hemiparesis;Sensory disturbance;Thrombotic cerebral infarction,216753441,OT,,,,,,,,,216753441,1,HIV infection
21687733,216877332,2,F,,20221128,20221206,20221207,EXP,,JP-ASTELLAS-2022EU000178,ASTELLAS,"Samukawa S, Yoshimi R, Kojitani N, Uzawa Y, Takase-Minegishi K, Kirino Y, et. al. Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report. Journal of Infection + Chemotherapy. 2022;unk:unk",43,YR,,M,Y,,,20221207,,HP,JP,JP,EFAVIRENZ,Drug ineffective,,,,,,,,,,,216877332,1,Meningitis cryptococcal
21693667,216936671,1,I,,20221204,20221207,20221207,EXP,,GB-MYLANLABS-2022M1136312,MYLAN,,,,,F,Y,,,20221207,,CN,GB,GB,EFAVIRENZ,Renal function test abnormal,216936671,OT,,,,,,,,,216936671,1,Product used for unknown indication
21693811,216938111,1,I,,20221202,20221207,20221207,EXP,,GB-MYLANLABS-2022M1136269,MYLAN,,,,,M,Y,,,20221207,,HP,GB,GB,EFAVIRENZ,Death,216938111,DE,,,,,,,,,216938111,1,Product used for unknown indication
21694819,216948192,2,F,,20221214,20221207,20221227,EXP,,PL-INSUD PHARMA-2211PL04988,INSUD PHARMA,,43,YR,,M,Y,,,20221227,,HP,PL,PL,EFAVIRENZ,Blood bilirubin increased;Clostridium difficile colitis;Conductive deafness;Diarrhoea;Drug ineffective;Drug resistance;Hepatitis cholestatic;Lymphopenia;Mental disorder;Myalgia;Nausea;Neuropsychiatric symptoms;Neutropenia;Pancreatitis;Pathogen resistance;Urinary tract infection;Urinary tract inflammation,216948192,HO,,,216948192,9,2011,,,,216948192,1,Enterobacter infection
21697546,216975461,1,I,,20221130,20221208,20221208,EXP,,CA-TEVA-2022-CA-2832794,TEVA,,,,,M,Y,,,20221208,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,216975461,HO,,,,,,,,,216975461,1,HIV infection
21698004,216980041,1,I,,20221130,20221208,20221208,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-148214,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20221208,,HP,CA,CA,SUSTIVA,Death,216980041,DE,,,,,,,,,216980041,1,HIV infection
21699720,216997201,1,I,20200801,20221130,20221208,20221208,EXP,,DK-MYLANLABS-2022M1135462,MYLAN,"Mens H, Fjordside L, Fonager J, Gerstoft J... Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART.. Emergence of the G118R Pan-Integrase.. 2022;14 (4):501-504",50,YR,,M,Y,,,20221208,,HP,DK,DK,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,216997201,OT,,,,,,,,,216997201,1,HIV infection
21699735,216997351,1,I,,20221205,20221208,20221208,EXP,,NVSC2022CA283120,NOVARTIS,,54,YR,,M,Y,,,20221208,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Product use in unapproved indication,216997351,DE,,,,,,,,,216997351,1,Bipolar disorder
21699859,216998591,1,I,20080901,20221202,20221208,20221208,EXP,,IN-MYLANLABS-2022M1137164,MYLAN,"Raja K, Chandrasekar C, Krishnarajasekhar O, Manoharan G. Zero CD4 count: A case of discordant CD4 response in a patient with well suppressed viral load. Indian-J-Med-Microbiol 2013;31(3):298-302.",5,DEC,,M,Y,,,20221208,,MD,IN,IN,EFAVIRENZ,Treatment failure,216998591,OT,,,216998591,4,200802,,,,216998591,1,HIV infection
21700178,217001781,1,I,,20221204,20221208,20221208,EXP,,GB-GILEAD-2022-0607627,GILEAD,,,,,F,Y,,,20221208,,CN,GB,GB,EFAVIRENZ,Renal function test abnormal;Renal impairment,217001781,OT,,,,,,,,,217001781,1,Product used for unknown indication
21706507,217065071,1,I,,20221130,20221209,20221209,EXP,,CA-009507513-2212CAN001004,MERCK,,63,YR,,F,Y,,,20221209,,HP,CA,CA,EFAVIRENZ,Alanine aminotransferase increased;Diarrhoea;Fatigue;Liver disorder;Low density lipoprotein increased;Mouth ulceration;Nausea;Nephrolithiasis;Osteoporosis;Renal disorder;Sleep terror;Type 2 diabetes mellitus,217065071,OT,,,,,,,,,,,
21706848,217068481,1,I,20100101,20221205,20221209,20221209,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME183265,VIIV,,,,,,Y,,,20221209,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217068481,HO,,,217068481,1,2003,2011,,,217068481,1,Antiretroviral therapy
21706849,217068491,1,I,20100101,20221205,20221209,20221209,EXP,,PT-GSK-PT2022EME183265,GLAXOSMITHKLINE,,,,,,Y,,,20221209,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217068491,HO,,,217068491,1,2003,2011,,,217068491,1,Antiretroviral therapy
21718480,217184801,1,I,,20221202,20221212,20221212,EXP,,CN-STRIDES ARCOLAB LIMITED-2022SP016657,STRIDES,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.. Front-Med. 2022;9:807013",40,YR,,M,Y,,,20221213,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vitritis,217184801,OT,,,,,,,,,217184801,1,Antiretroviral therapy
21718481,217184811,1,I,,20221202,20221212,20221212,EXP,,CN-STRIDES ARCOLAB LIMITED-2022SP016659,STRIDES,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.. Front-Med. 2022;9807013.",50,YR,,M,Y,,,20221213,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vitritis,217184811,OT,,,,,,,,,217184811,1,HIV infection
21718653,217186531,1,I,,20221128,20221213,20221213,EXP,,GB-CIPLA LTD.-2022GH07091,CIPLA,"Villa G, Gerett AM, Owusu D, Smith C, Azumah M, Abdullahi A et al.. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications. 2022;6:3036 to 3051",61,YR,,M,Y,,,20221213,,HP,GB,GH,EFAVIRENZ,Drug resistance,217186531,OT,,,,,,,,,217186531,1,HIV infection
21718656,217186561,1,I,,20221128,20221213,20221213,EXP,,GB-CIPLA LTD.-2022GH07089,CIPLA,"Villa G, Geretti AM, Owusu D, Smith C, Azumah M, Abdullahi A et al.. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications. 2022;6:3036 to 3051",48,YR,,M,Y,,,20221213,,HP,GB,GH,EFAVIRENZ,Drug resistance,217186561,OT,,,,,,,,,217186561,1,HIV infection
21718713,217187131,1,I,,20221128,20221213,20221213,EXP,,GB-CIPLA LTD.-2022GH07090,CIPLA,"Villa G, Geretti AM, Owusu D, Smith C, Azumah M, Abdullahi A et al.. Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection. Hepatology Communications. 2022;6:3036 to 3051",48,YR,,F,Y,,,20221213,,HP,GB,GH,EFAVIRENZ,Drug resistance,217187131,OT,,,,,,,,,217187131,1,HIV infection
21720436,217204361,1,I,,20221202,20221213,20221213,EXP,,CN-STRIDES ARCOLAB LIMITED-2022SP016660,STRIDES,"Qian Y, Wang L, Jiang J, Suo J, Weng H, Che X, et al.. Cytomegalovirus-Immune Recovery Retinitis After Initiation of Highly Active Antiretroviral Therapy: A Case Series.. Front-Med. 2022;9807013",54,YR,,M,Y,,,20221213,,HP,CN,CN,EFAVIRENZ,Cytomegalovirus chorioretinitis;Haemorrhage;Immune reconstitution inflammatory syndrome;Necrotising retinitis;Vitritis,217204361,OT,,,,,,,,,217204361,1,HIV infection
21721929,217219291,1,I,,20221026,20221213,20221213,EXP,,CA-GSK-CA2022159840,GLAXOSMITHKLINE,,,,,,Y,,,20221213,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,217219291,HO,,,,,,,,,217219291,1,Product used for unknown indication
21721930,217219301,1,I,,20221026,20221213,20221213,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022159840,VIIV,,,,,,Y,,,20221213,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,217219301,OT,,,,,,,,,217219301,1,Product used for unknown indication
21725199,217251991,1,I,,20211229,20221214,20221214,EXP,,CA-ALVOGEN-2021085707,ALVOGEN,,54,YR,,M,Y,,,20221214,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,217251991,OT,,,,,,,,,217251991,1,Bipolar disorder
21726772,217267721,1,I,20040101,20221212,20221214,20221214,EXP,,US-VIIV HEALTHCARE LIMITED-US2022AMR185796,VIIV,,,,,,Y,,,20221214,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Metastatic lymphoma;Prostate cancer,217267721,OT,,,,,,,,,217267721,1,HIV infection
21727271,217272711,1,I,,20211229,20221214,20221214,EXP,,CA-ALVOGEN-2021085718,ALVOGEN,,54,YR,,M,Y,,,20221214,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,217272711,OT,,,,,,,,,217272711,1,Bipolar disorder
21730259,217302591,1,I,,20221207,20221214,20221214,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-152236,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20221215,,CN,US,US,SUSTIVA,Panic attack,,,,,217302591,1,2005,,,,217302591,1,HIV infection
21732132,217321321,1,I,,20221209,20221215,20221215,EXP,,US-ABBVIE-4233910,ABBVIE,,54,YR,,M,Y,,,20221215,,CN,US,US,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,217321321,HO,,,,,,,,,217321321,1,Product used for unknown indication
21733094,217330941,1,I,,20221210,20221215,20221215,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2022APC187026,VIIV,,,,,,Y,,,20221215,,MD,TW,TW,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Death,217330941,OT,,,,,,,,,217330941,1,Product used for unknown indication
21738851,217388511,1,I,,20221205,20221216,20221216,EXP,,US-CIPLA (EU) LIMITED-2022US07153,CIPLA,"Kilcrease C, Agwu AL, Yusuf H, Park J, Powell A, James L et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19:56:1 to 6",,,,F,Y,,,20221216,,HP,US,US,EFAVIRENZ,Drug resistance;Immunosuppression;Molluscum contagiosum;Mycobacterium avium complex infection;Pneumonia;Treatment noncompliance;Vaginal infection;Virologic failure,217388511,HO,,,,,,,,,217388511,1,HIV infection
21738852,217388521,1,I,,20221205,20221216,20221216,EXP,,US-CIPLA LTD.-2022US07155,CIPLA,"Kilcrease C, Agwu AL, Yusuf H, Park J, Powell A, James L et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19 (56):1 to 6",,,,F,Y,,,20221216,,HP,US,US,EFAVIRENZ,Adverse drug reaction;Drug resistance;Immunosuppression;Infection;Mucocutaneous candidiasis;Nausea;Onychomycosis;Oral candidiasis;Pneumonia;Product use complaint;Pyelonephritis;Somnolence;Treatment noncompliance;Varicella;Virologic failure,217388521,OT,,,,,,,,,217388521,1,HIV infection
21739101,217391011,1,I,,20221204,20221216,20221216,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2022038769,MACLEODS,,,,,,Y,,,20221216,,CN,GB,GB,EFAVIRENZ,Renal function test abnormal,217391011,OT,,,,,,,,,217391011,1,Product used for unknown indication
21739924,217399241,1,I,,20221212,20221216,20221216,EXP,,IN-GILEAD-2022-0609375,GILEAD,"Parvez S., Goel P., Sarna M, Rijhwani P... HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. Indian Academy of Clinical Medicine. 2022;23(3-4):154-156. doi:Unk",30,YR,A,M,Y,,,20221216,,HP,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome,217399241,OT,,,,,,,,,217399241,1,HIV infection
21742020,217420201,1,I,20171006,20221206,20221216,20221216,EXP,,GB-TEVA-2022-GB-2835817,TEVA,,3,MON,I,M,Y,,,20221216,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Cleft lip and palate;Foetal exposure during pregnancy;Hepatic cytolysis;Hydrops foetalis;Off label use;Trisomy 18;Ultrasound antenatal screen,217420201,CA,,,217420201,1,20100610,20180205,4,YR,217420201,1,Product used for unknown indication
21743058,217430581,1,I,,20221214,20221217,20221217,EXP,,CA-ABBVIE-4239153,ABBVIE,,44,YR,,M,Y,,,20221217,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,217430581,HO,,,,,,,,,217430581,1,HIV infection
21744219,217442191,1,I,,20221204,20221218,20221218,EXP,,GB-AUROBINDO-AUR-APL-2022-053470,AUROBINDO,,,,,F,Y,,,20221218,,CN,GB,GB,EFAVIRENZ,Renal function test abnormal,217442191,OT,,,,,,,,,217442191,1,Product used for unknown indication
21744610,217446101,1,I,,20221209,20221218,20221218,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP016970,STRIDES,"Samukawa S, Yoshimi R, Kojitani N, Uzawa Y, Takase-Minegishi K, Kirino Y, et al.. Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.. J-Infect-Chemother. 2022;no pagination.",5,DEC,,M,Y,,,20221219,,HP,JP,JP,EFAVIRENZ,Altered state of consciousness;Aphasia;Cognitive disorder;Epilepsy;Hemiparesis;Immune reconstitution inflammatory syndrome;Sensory disturbance,217446101,OT,,,217446101,4,,,6,MON,217446101,1,HIV infection
21747669,217476691,1,I,,20221215,20221219,20221219,EXP,,GB-GILEAD-2022-0609482,GILEAD,,,,,M,Y,,,20221219,,HP,GB,GB,EFAVIRENZ,Death,217476691,DE,,,,,,,,,217476691,1,Product used for unknown indication
21749395,217493951,1,I,,20221205,20221219,20221219,EXP,,ES-GSK-PA2022GSK183682,GLAXOSMITHKLINE,,,,,,Y,,,20221219,,HP,ES,PA,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217493951,OT,,,,,,,,,217493951,1,Perinatal HIV infection
21749399,217493991,1,I,,20221205,20221219,20221219,EXP,,ES-VIIV HEALTHCARE LIMITED-PA2022GSK183682,VIIV,,,,,,Y,,,20221219,,HP,ES,PA,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217493991,OT,,,,,,,,,217493991,1,Perinatal HIV infection
21749543,217495431,1,I,20221204,20221207,20221219,20221219,EXP,,CN-GSK-CN2022APC184665,GLAXOSMITHKLINE,,,,,,Y,,,20221214,,HP,CN,CN,EFAVIRENZ,Decreased appetite;Pathogen resistance,217495431,OT,,,217495431,1,20221202,20221205,3,DAY,217495431,1,HIV infection
21749564,217495641,1,I,20221204,20221207,20221219,20221219,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC184665,VIIV,,,,,,Y,,,20221214,,HP,CN,CN,EFAVIRENZ,Decreased appetite;Pathogen resistance,217495641,OT,,,217495641,1,20221202,20221205,3,DAY,217495641,1,HIV infection
21750640,217506401,1,I,,20221205,20221219,20221219,EXP,,NL-GILEAD-2022-0608128,GILEAD,"Gordijn R, Wessels W, Kriek E, Nicolai P J M, Elzevier W H, Visser L etal. Patient reporting of sexual adverse events on an online platform for medication experiences. British Journal of Clinical Pharmacology. 2022;88(12):5326-5335. doi:10.1111/bcp.15454",,,,M,Y,,,20221219,,HP,NL,NL,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Sexual dysfunction,217506401,OT,,,,,,,,,217506401,1,Product used for unknown indication
21754551,217545511,1,I,,20221214,20221220,20221220,EXP,,CA-APOTEX-2022AP016890,APOTEX,,54,YR,,M,Y,,,20221220,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,217545511,OT,,,,,,,,,217545511,1,HIV infection
21760342,217603421,1,I,,20221214,20221221,20221221,EXP,,CA-APOTEX-2022AP016900,APOTEX,,54,YR,,M,Y,,,20221221,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,217603421,OT,,,,,,,,,217603421,1,HIV infection
21762630,217626301,1,I,,20221212,20221221,20221221,EXP,,IN-GSK-IN2022GSK186259,GLAXOSMITHKLINE,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. Journal, Indian Academy of Clinical Medicine. 2022;23(3-4):154-156",,,,,Y,,,20221221,,MD,IN,IN,EFAVIRENZ,Gingival hypertrophy;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Rash;Skin hyperpigmentation;Skin lesion;Skin mass;Skin plaque,217626301,OT,,,,,,,,,217626301,1,HIV infection
21762631,217626311,1,I,,20221212,20221221,20221221,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK186259,VIIV,"Parvez S, Goel P, Sarna MK, Rijhwani P. HIV-Associated Cutaneous Kaposi^s Sarcoma induced by IRIS following Antiretroviral Therapy. Journal, Indian Academy of Clinical Medicine. 2022;23(3-4):154-156",,,,,Y,,,20221221,,MD,IN,IN,EFAVIRENZ,Gingival hypertrophy;Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma;Kaposi's sarcoma;Rash;Skin hyperpigmentation;Skin lesion;Skin mass;Skin plaque,217626311,OT,,,,,,,,,217626311,1,HIV infection
21763902,217639021,1,I,,20221214,20221222,20221222,EXP,,CA-APOTEX-2022AP016921,APOTEX,,54,YR,,M,Y,,,20221222,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,217639021,HO,,,,,,,,,217639021,1,Depression
21767060,217670601,1,I,,20221215,20221222,20221222,EXP,,GB-TEVA-2022-GB-2838629,TEVA,,,,,M,Y,,,20221222,,HP,GB,GB,EFAVIRENZ,Death,217670601,DE,,,,,,,,,217670601,1,Product used for unknown indication
21769521,217695211,1,I,,20221214,20221223,20221223,EXP,,CA-APOTEX-2022AP016931,APOTEX,,54,YR,,M,Y,,,20221223,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,217695211,OT,,,,,,,,,217695211,1,HIV infection
21769977,217699771,1,I,,20221216,20221223,20221223,EXP,,CA-TEVA-2022-CA-2838176,TEVA,,54,YR,A,M,Y,,,20221223,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,217699771,DE,,,,,,,,,217699771,1,Product used for unknown indication
21770839,217708391,1,I,,20221212,20221223,20221223,EXP,,IN-CIPLA LTD.-2022IN07290,CIPLA,"Parvez S, Goel P, Sarna MK, Rijhwani P.. HIV-Associated Cutaneous Kaposi?s Sarcoma induced by IRIS following Antiretroviral Therapy. Journal, Indian Academy of Clinical Medicine. 2022;23 (3 to 4):154 to 156",30,YR,,M,Y,,,20221223,,MD,IN,IN,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma,217708391,OT,,,,,,,,,217708391,1,HIV infection
21771686,217716861,1,I,,20221214,20221223,20221223,EXP,,CA-APOTEX-2022AP016894,APOTEX,,44,YR,,M,Y,,,20221223,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,217716861,HO,,,,,,,,,217716861,1,Depression
21771945,217719451,1,I,20100101,20221215,20221223,20221223,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-154808,BRISTOL MYERS SQUIBB,,77,YR,E,M,Y,,,20221223,,CN,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217719451,OT,,,217719451,1,2003,2017,6,YR,217719451,1,Antiretroviral therapy
21773178,217731781,1,I,,20221215,20221223,20221223,EXP,,US-PFIZER INC-PV202200125940,PFIZER,"Kilcrease, C.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19(1):10.1186/s12981-022-00477-w",37,YR,,F,Y,,,20221223,,HP,US,US,EFAVIRENZ,Treatment noncompliance,217731781,OT,,,,,,,,,217731781,1,HIV infection
21777000,217770001,1,I,,20221214,20221226,20221226,EXP,,CA-APOTEX-2022AP016875,APOTEX,,,,,M,Y,,,20221226,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,217770001,HO,,,,,,,,,217770001,1,Product used for unknown indication
21778231,217782311,1,I,,20221216,20221226,20221226,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2022GSK188297,VIIV,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. Southern African journal of HIV medicine. 2022;23(1)",,,,,Y,,,20221226,,MD,ZW,ZW,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,217782311,OT,,,,,,,,,217782311,1,HIV infection
21778275,217782751,1,I,,20221214,20221226,20221226,EXP,,CA-APOTEX-2022AP016932,APOTEX,,54,YR,,M,Y,,,20221226,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,217782751,OT,,,,,,,,,217782751,1,HIV infection
21781145,217811451,1,I,,20221212,20221227,20221227,EXP,,IN-AUROBINDO-AUR-APL-2022-054276,AUROBINDO,"Raja K, Chandrasekar C, Krishnarajasekhar O, Manoharan G.. Zero CD4 count: A case of discordant CD4 response in a patient with well suppressed viral load. Indian-J-Med-Microbiol. 2013;31(3):298-302",49,YR,,M,Y,59,KG,20221227,,HP,IN,IN,EFAVIRENZ,Treatment failure,217811451,OT,,,217811451,3,200802,,,,217811451,1,HIV infection
21787127,217871271,1,I,,20221214,20221228,20221228,EXP,,ES-AUROBINDO-AUR-APL-2022-054940,AUROBINDO,"Ventosa-Cubillo J, Pinzon R, Gonzalez-Alba JM, Estripeaut D, Navarro ML, Holguin A. Drug resistance in children and adolescents with HIV in Panama. The Journal of antimicrobial chemotherapy. 2022",15,YR,,,Y,,,20221228,,HP,ES,ES,EFAVIRENZ,HIV viraemia;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,217871271,OT,,,,,,,,,217871271,1,Perinatal HIV infection
21791563,217915631,1,I,,20221218,20221228,20221228,EXP,,US-JNJFOC-20221243253,JOHNSON AND JOHNSON,,,,,,Y,,,20221229,,HP,US,US,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Drug-induced liver injury;Stevens-Johnson syndrome,217915631,OT,,,,,,,,,217915631,1,Product used for unknown indication
21791687,217916871,1,I,20221207,20221220,20221229,20221229,EXP,,RU-HETERO-HET2022RU03177,HETERO,,34,YR,,F,Y,,,20221229,,CN,RU,RU,EFAVIRENZ,Pruritus;Rash;Swelling face,217916871,HO,,,217916871,1,20221128,20221207,10,DAY,217916871,1,HIV infection
21791795,217917951,1,I,,20221215,20221229,20221229,EXP,,GB-MACLEODS PHARMA EU LTD-MAC2022038928,MACLEODS,,,,,,Y,,,20221228,,HP,GB,GB,EFAVIRENZ,Death,217917951,DE,,,,,,,,,217917951,1,Product used for unknown indication
21793519,217935191,1,I,20100101,20221215,20221229,20221229,EXP,,PT-AUROBINDO-AUR-APL-2022-055163,AUROBINDO,,77,YR,,M,Y,,,20221229,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Chronic kidney disease;Depression;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Lipodystrophy acquired;Osteoporosis;Renal mass,217935191,HO,,,217935191,1,2011,2017,,,217935191,1,Antiretroviral therapy
21802785,218027851,1,I,,20221217,20221231,20221231,EXP,,CA-MYLANLABS-2022M1148930,MYLAN,,44,YR,,M,Y,,,20221231,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,218027851,HO,,,,,,,,,218027851,1,Bipolar disorder
6759866,67598662,2,F,,20220921,20080916,20221006,EXP,,US-RANBAXY-2008RR-17909,RANBAXY,"Trivedi BS, Libman H. Update: A 39-year-old man with HIV-associated lipodystrophy. JAMA. 2011;Jul 6; 306(1):87",39,YR,,M,Y,,,20221006,,HP,US,US,EFAVIRENZ,Anaemia;Lipodystrophy acquired;Neuropathy peripheral;Rash,67598662,OT,,,67598662,2,200402,2003,,,67598662,1,HIV infection
7152253,715225314,14,F,,20220929,20091019,20221010,EXP,,CA-PFIZER INC-2009279889,PFIZER,"Pfeffer, G.. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology. 2009;73 (1):71-72",52,YR,,M,Y,,,20221010,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715225314,OT,,,715225314,1,,,274,DAY,715225314,1,HIV infection
7302622,730262243,43,F,,20221118,20100302,20221124,EXP,,CA-MERCK-0907CAN00093,MERCK,"Pfeffer G, Mezei MM, Montaner JS, Li CC, Jitratkosol M, Cote HC. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. NEUROLOGY. 2009;73(1):71-2",52,YR,,M,Y,,,20221124,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,730262243,OT,,,730262243,1,200802,200802,91,DAY,730262243,1,HIV infection
